{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":191,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":191,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"fdc8860e50c3","filters":{"venue":"Investigational New Drugs"}},"results":[{"id":"W1964185052","doi":"10.1007/s10637-010-9399-1","title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Population; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Doxorubicin; Chemotherapy; Adenocarcinoma; Surgery; Esophagus; Progressive disease; Oncology; Cancer; Clinical trial","authors":[{"name":"Juan W. Valle","is_ca":false},{"name":"Anne Armstrong","is_ca":false},{"name":"Chris Newman","is_ca":true},{"name":"Valery Yu. Alakhov","is_ca":true},{"name":"Grzegorz Pietrzyński","is_ca":true},{"name":"Julie Brewer","is_ca":false},{"name":"Sue Campbell","is_ca":true},{"name":"Pippa Corrie","is_ca":false},{"name":"Eric K. Rowinsky","is_ca":true},{"name":"Malcolm Ranson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007041558149605497,"gpt":0.2578805014282209,"spread":0.2508389432786154,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002141384,0.0001482466,0.0002739447,0.0002116923,0.0000392554,0.000006897221,0.00009643167,0.00004463815,0.00002634484],"category_scores_gemma":[0.0001598526,0.0001016073,0.00002909549,0.0004667338,0.0001890847,0.0001220488,0.00005526442,0.0003643672,7.875475e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009109238,"about_ca_system_score_gemma":0.0004503657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009519833,"about_ca_topic_score_gemma":0.0005174655,"domain_scores_codex":[0.9983971,0.00006729565,0.0003926016,0.0002704022,0.0006577692,0.0002147926],"domain_scores_gemma":[0.9992583,0.00006305828,0.0001828687,0.0002154829,0.0001179533,0.0001623802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001289699,0.001630354,0.9921216,0.00005596105,0.00002969836,0.00001953116,0.001319771,0.00009823494,0.0006088818,0.0001317147,0.00001689647,0.002677636],"study_design_scores_gemma":[0.02746983,0.00338679,0.9581348,0.000120213,0.00002708713,0.000003049591,0.0002502149,0.00008891109,0.01013167,0.0003271627,0.000001945568,0.00005831354],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969662,0.001086592,0.000002284782,0.0003481326,0.00005121277,0.001503221,0.00001085948,0.000007165334,0.00002427517],"genre_scores_gemma":[0.9986595,0.000002365068,0.001100957,0.0000576267,0.00004121948,0.00005138132,0.00002610733,0.00001585235,0.0000450079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0339868,"threshold_uncertainty_score":0.4143426,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2088460013","doi":"10.1007/s10637-014-0082-9","title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Rash; Internal medicine; Cancer; Adverse effect; Pharmacodynamics; Breast cancer; Oncology; Tolerability; Phases of clinical research; Colorectal cancer; Clinical trial; Gastroenterology; Pharmacokinetics","authors":[{"name":"Jordi Rodón","is_ca":false},{"name":"Irene Braña","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Maja J. De Jonge","is_ca":false},{"name":"Natasha F Homji","is_ca":false},{"name":"David Mills","is_ca":false},{"name":"Emmanuelle di Tomaso","is_ca":false},{"name":"Céline Sarr","is_ca":false},{"name":"Lucia Trandafir","is_ca":false},{"name":"Cristian Massacesi","is_ca":false},{"name":"Ferry A.L.M. Eskens","is_ca":false},{"name":"Johanna C. Bendell","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009291892874384198,"gpt":0.2711400666733916,"spread":0.2618481737990074,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001997955,0.0001853241,0.0002104069,0.00008207803,0.00005513482,0.00002021767,0.0001220561,0.00009356335,0.000005812985],"category_scores_gemma":[0.0001034273,0.0001719314,0.00002111927,0.0001558251,0.0001318307,0.00003576273,0.00005387871,0.0001009546,0.000001196991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003041808,"about_ca_system_score_gemma":0.0002038213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001302451,"about_ca_topic_score_gemma":0.0001409978,"domain_scores_codex":[0.998553,0.0001201559,0.0003629813,0.0004251549,0.0003613275,0.0001773212],"domain_scores_gemma":[0.9991944,0.00002737264,0.0002039013,0.0002514329,0.0001683247,0.00015459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001868044,0.003384787,0.4596075,0.00005806112,0.00008185893,0.000002075337,0.002267598,0.008666178,0.4879538,0.000218829,0.0005894423,0.03530182],"study_design_scores_gemma":[0.034571,0.01680435,0.7259006,0.0002549038,0.00006336079,0.000003024565,0.0005248601,0.003477629,0.2150441,0.00160081,0.0009042688,0.0008511006],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991876,0.00003207468,0.000150605,0.00006978363,0.00008611647,0.0003972122,0.00001672633,0.00001250399,0.00004730444],"genre_scores_gemma":[0.9980095,0.000002238059,0.001234765,0.0001940317,0.0001436106,0.00002457949,0.0003358784,0.00002664646,0.00002873914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2729097,"threshold_uncertainty_score":0.701116,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1902804987","doi":"10.1007/s10637-015-0282-y","title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Pharmacokinetics; Nausea; Vomiting; Dosing; Tyrosine-kinase inhibitor; Gastroenterology; Pharmacology; Internal medicine; Cancer","authors":[{"name":"Suzanne F. Jones","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Johanna C. Bendell","is_ca":false},{"name":"James M. Cleary","is_ca":false},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Jeffrey R. Infante","is_ca":false},{"name":"Shuchi S. Pandya","is_ca":false},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Kristen J. Pierce","is_ca":false},{"name":"Brett E. Houk","is_ca":false},{"name":"W. Gregory Roberts","is_ca":false},{"name":"S. Martin Shreeve","is_ca":false},{"name":"Geoffrey I. Shapiro","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03517182792736757,"gpt":0.3173592460625452,"spread":0.2821874181351777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000292536,0.0001950863,0.0003538433,0.0003558789,0.00004224343,0.00001787783,0.0001069979,0.00007008254,0.00008702034],"category_scores_gemma":[0.000412082,0.0001669092,0.0000380257,0.0005778013,0.000117183,0.0002164561,0.00007078644,0.0002550691,0.00002841657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002175964,"about_ca_system_score_gemma":0.001380936,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001396468,"about_ca_topic_score_gemma":0.0001496586,"domain_scores_codex":[0.997309,0.0001392012,0.0005538125,0.0003970401,0.001353682,0.0002472825],"domain_scores_gemma":[0.9983844,0.00006395006,0.0001701852,0.0002861113,0.0005205198,0.000574789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01947568,0.03506401,0.5159275,0.0003640238,0.0002052739,0.0003982281,0.02249014,0.004218921,0.3496954,0.000398091,0.02448821,0.0272745],"study_design_scores_gemma":[0.2163035,0.05690389,0.395855,0.001027272,0.0001363477,0.00002539757,0.003603056,0.0102042,0.3119786,0.001263911,0.001647289,0.001051437],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979054,0.00003126123,0.00002109809,0.0004470883,0.00006284426,0.001294834,0.00001217599,0.00002575422,0.0001995978],"genre_scores_gemma":[0.9970055,7.02232e-7,0.001728968,0.0003269415,0.0001348212,0.00005663498,0.0002876549,0.00003255285,0.0004262543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1968279,"threshold_uncertainty_score":0.6806358,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2063432158","doi":"10.1007/s10637-011-9719-0","title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Internal medicine; Gallbladder; Gastroenterology; Oncology; Carcinoma; Hepatocellular carcinoma; Stage (stratigraphy); Chemotherapy; Gallbladder cancer","authors":[{"name":"Anthony B. El-Khoueiry","is_ca":false},{"name":"Cathryn Rankin","is_ca":false},{"name":"Edgar Ben‐Josef","is_ca":false},{"name":"Heinz‐Josef Lenz","is_ca":false},{"name":"Philip J. Gold","is_ca":false},{"name":"Robert D. Hamilton","is_ca":false},{"name":"Rangaswamy Govindarajan","is_ca":false},{"name":"Cathy Eng","is_ca":false},{"name":"Charles D. Blanke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04928934074195547,"gpt":0.2755956105989698,"spread":0.2263062698570143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001685451,0.0002907109,0.0005609201,0.0003222277,0.0001150042,0.00001564245,0.0001319977,0.00004808616,0.0001720808],"category_scores_gemma":[0.00009639157,0.0002113276,0.00005142192,0.0005470364,0.0002140785,0.0002445069,0.0001274822,0.0002025506,0.000004610255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006807921,"about_ca_system_score_gemma":0.0004839834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002359364,"about_ca_topic_score_gemma":0.0006031462,"domain_scores_codex":[0.9980156,0.0000684161,0.0004929614,0.0004605908,0.0006408435,0.0003215578],"domain_scores_gemma":[0.9988922,0.00008556877,0.000177569,0.000314365,0.0002297044,0.0003005452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002773886,0.002649629,0.9667405,0.00009850991,0.0002914624,0.00007534537,0.02529863,0.000003297731,0.00006865727,0.0001309834,0.001018159,0.0008508767],"study_design_scores_gemma":[0.02863069,0.007605258,0.9594144,0.000115214,0.0003039716,0.00001496835,0.002626058,0.00003715655,0.0005756683,0.0003622194,0.00007761538,0.0002367841],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970173,0.0004017659,0.00000635416,0.000265319,0.00005264004,0.001174683,0.00002562849,0.00002853249,0.001027823],"genre_scores_gemma":[0.9972536,0.00000393447,0.001515989,0.000366618,0.00005952253,0.00007606511,0.0000485926,0.00003655688,0.0006391178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0258568,"threshold_uncertainty_score":0.8617691,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966040155","doi":"10.1007/s10637-007-9044-9","title":"Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Hamilton Health Sciences; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Nausea; Adverse effect; Internal medicine; Neutropenia; Urology; Vomiting; Clinical trial; Gastroenterology; Oncology; Surgery; Toxicity","authors":[{"name":"Jennifer J. Knox","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Eric Winquist","is_ca":true},{"name":"B. Fisher","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05282090444412633,"gpt":0.3459315138132732,"spread":0.2931106093691468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001704004,0.0001342279,0.0004160907,0.00007003818,0.00004337076,0.0000036088,0.0002063989,0.00006302748,0.000009933545],"category_scores_gemma":[0.001354132,0.000100369,0.00009540581,0.0002417966,0.0001736547,0.000007216369,0.00008359074,0.0001081109,4.689382e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007766487,"about_ca_system_score_gemma":0.004816633,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03811641,"about_ca_topic_score_gemma":0.1154236,"domain_scores_codex":[0.9975419,0.0001948491,0.001273906,0.0002368459,0.0006110919,0.0001414252],"domain_scores_gemma":[0.9982305,0.0002767801,0.0008788838,0.0001726398,0.0003306527,0.0001106058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2253627,0.04564031,0.56725,0.0003871221,0.00215143,0.00001292386,0.003873694,0.02582391,0.06965315,0.003386974,0.04451177,0.01194607],"study_design_scores_gemma":[0.556308,0.01757344,0.3311962,0.0001332791,0.0004726827,0.000001149175,0.000330974,0.0001157056,0.08563818,0.001202083,0.006438648,0.0005896676],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979506,0.00008742953,0.00004323073,0.000121465,0.0004525641,0.0009279153,0.0003216102,7.765028e-7,0.00009440499],"genre_scores_gemma":[0.9989206,0.000005906343,0.0003824404,0.0002052539,0.0002726134,0.00002328883,0.0001181976,0.00001021635,0.00006146987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3309453,"threshold_uncertainty_score":0.9682888,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2028577286","doi":"10.1007/s10637-009-9279-8","title":"Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Viral shedding; Medicine; Viral load; Neutralizing antibody; Virology; Antibody; Virus; Viral replication; Chemotherapy; Oncolytic virus; Immunology; Internal medicine","authors":[{"name":"R. Gollamudi","is_ca":false},{"name":"Mohammad H. Ghalib","is_ca":false},{"name":"Kavita Desai","is_ca":false},{"name":"Imran Chaudhary","is_ca":false},{"name":"Benny Wong","is_ca":false},{"name":"Mark H. Einstein","is_ca":false},{"name":"Matthew Coffey","is_ca":true},{"name":"George M. Gill","is_ca":true},{"name":"K.L. Mettinger","is_ca":true},{"name":"John M. Mariadason","is_ca":false},{"name":"Sridhar Mani","is_ca":false},{"name":"Sanjay Goel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01033617842663142,"gpt":0.2731821496401648,"spread":0.2628459712135334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001580831,0.0001428218,0.0001589255,0.00008283729,0.00004476904,0.00001323882,0.0001734789,0.00007667726,0.00003075244],"category_scores_gemma":[0.00007708716,0.0001400136,0.00004012897,0.0001953405,0.0001133249,0.00001306715,0.00002053843,0.000100367,0.00001014913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004896632,"about_ca_system_score_gemma":0.0006023982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003745894,"about_ca_topic_score_gemma":0.00008433563,"domain_scores_codex":[0.9986335,0.00006234011,0.0003503884,0.0003896301,0.0003780204,0.000186122],"domain_scores_gemma":[0.9990211,0.00001422955,0.0001997563,0.0004076894,0.0002262662,0.0001309236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006325241,0.0005493256,0.005018157,0.00001931117,0.00005748115,0.0000029368,0.0008071093,0.001363684,0.9571577,0.0003398225,0.0006718562,0.02768733],"study_design_scores_gemma":[0.001735942,0.005606478,0.1121703,0.00006083228,0.000007833864,0.000002486536,0.00003681834,0.0001255608,0.8778436,0.001992752,0.0002219091,0.0001954882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980139,0.00009153695,0.00007788435,0.001133115,0.0000149039,0.0003893256,0.00003679462,0.000007644964,0.0002348611],"genre_scores_gemma":[0.9961183,0.00002567643,0.002000017,0.001029318,0.00006474605,0.00001676321,0.000603847,0.00001417363,0.0001271603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1071521,"threshold_uncertainty_score":0.570959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","authors":[{"name":"Siqing Fu","is_ca":false},{"name":"Hal W. Hirte","is_ca":true},{"name":"Stephen Welch","is_ca":true},{"name":"T. Toney Ilenchuk","is_ca":true},{"name":"Tyler Lutes","is_ca":true},{"name":"Christopher Rice","is_ca":true},{"name":"Nigel Fields","is_ca":false},{"name":"Agnes Nemet","is_ca":false},{"name":"Dominique Dugourd","is_ca":true},{"name":"Sarina A. Piha‐Paul","is_ca":false},{"name":"V. Subbiah","is_ca":false},{"name":"L. Liu","is_ca":false},{"name":"Jing Gong","is_ca":false},{"name":"David S. Hong","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03587327682816752,"gpt":0.3115781625913163,"spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001472079,0.0002229572,0.000321848,0.000237565,0.0003192041,0.00005452413,0.0004345933,0.00006277249,0.00002819108],"category_scores_gemma":[0.0003162748,0.0001885213,0.00004065797,0.0002364386,0.00031575,0.0004960103,0.0001146667,0.0002206815,0.00001148593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007192917,"about_ca_system_score_gemma":0.000187147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005394027,"about_ca_topic_score_gemma":0.0002557347,"domain_scores_codex":[0.9979633,0.00007268408,0.0004977415,0.0004987543,0.0006480988,0.0003194262],"domain_scores_gemma":[0.9989287,0.00008326452,0.000418802,0.0002941811,0.00007699652,0.0001981032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004080785,0.04510146,0.5133196,0.0005868485,0.0001045728,0.0003409757,0.1472217,0.1055449,0.1654172,0.006776556,0.006697364,0.004808026],"study_design_scores_gemma":[0.07106864,0.006063308,0.3551559,0.001383645,0.00003130038,0.000005031222,0.002546733,0.005308366,0.5455379,0.01099545,0.0003484873,0.001555189],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979638,0.000004454456,0.000007003036,0.0005890472,0.0003531634,0.0007553838,0.00002345476,0.00002217766,0.0002815362],"genre_scores_gemma":[0.9992567,0.00000122249,0.00005279837,0.0001712517,0.0001323732,0.0000393431,0.00001185949,0.0000267872,0.0003077131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3801208,"threshold_uncertainty_score":0.7687674,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989987919","doi":"10.1007/s10637-006-5938-1","title":"Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Pyrogenesis (Canada); Queen's University; London Health Sciences Centre; Hôpital Notre-Dame; Princess Margaret Cancer Centre; University Health Network; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Medical Research Council; University Health Network","keywords":"Clinical trial; Medicine; Renal cell carcinoma; Cancer; Phases of clinical research; Drug; Oncology; Cancer drugs; Internal medicine; Pharmacology","authors":[{"name":"Eric Winquist","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Jean-Pierre M. Ayoub","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"Gregory K. Reid","is_ca":true},{"name":"Laura Pearce","is_ca":true},{"name":"Ajit Shah","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03687109437820722,"gpt":0.3202348674483818,"spread":0.2833637730701745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001999899,0.0002630522,0.0005093298,0.0001289162,0.000133433,0.0000197205,0.000156263,0.00007466273,0.00001683836],"category_scores_gemma":[0.0005543831,0.0001906013,0.0001049852,0.0004070583,0.0003683377,0.00003689914,0.00004157131,0.0001747504,2.110804e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007713508,"about_ca_system_score_gemma":0.005775711,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0730341,"about_ca_topic_score_gemma":0.1738885,"domain_scores_codex":[0.9961763,0.0006963005,0.001349266,0.0004469519,0.001117201,0.0002139974],"domain_scores_gemma":[0.9980666,0.0002891591,0.0007331775,0.0002203996,0.0004935536,0.0001970927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09238487,0.02213201,0.3971632,0.000235843,0.00298112,0.00004494314,0.003030738,0.115294,0.303438,0.01183384,0.04374901,0.007712444],"study_design_scores_gemma":[0.3365597,0.01022512,0.3880836,0.0002553957,0.0008332907,0.000003209007,0.0002722959,0.0006133196,0.2500041,0.008932951,0.003117298,0.001099651],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960721,0.0001502334,0.0005168872,0.001270731,0.0001721354,0.001396217,0.0003504071,0.000004653006,0.00006667056],"genre_scores_gemma":[0.9957299,0.00000786487,0.002185426,0.0002197665,0.0004721833,0.00006199135,0.001162894,0.00002451767,0.0001354311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2441748,"threshold_uncertainty_score":0.9998606,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2092271538","doi":"10.1007/s10637-015-0221-y","title":"A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":130,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Internal medicine; Tolerability; Toxicity; Gastroenterology; Adverse effect; Surgery; Urology","authors":[{"name":"Quincy S. Chu","is_ca":true},{"name":"Randeep Sangha","is_ca":true},{"name":"Jennifer L. Spratlin","is_ca":true},{"name":"Larissa J. Vos","is_ca":true},{"name":"John R. Mackey","is_ca":true},{"name":"Alexander McEwan","is_ca":true},{"name":"Peter Venner","is_ca":true},{"name":"Evangelos D. Michelakis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0252872114905891,"gpt":0.2869394494576427,"spread":0.2616522379670536,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001894371,0.0001858991,0.0002721391,0.00008309523,0.0000421578,0.00003187073,0.000274359,0.000061129,0.000008841376],"category_scores_gemma":[0.0001476036,0.0001719343,0.00002648906,0.000268426,0.000112819,0.00003569258,0.0001285702,0.0000838491,0.000003651164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003417101,"about_ca_system_score_gemma":0.0005886855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001904543,"about_ca_topic_score_gemma":0.0002211469,"domain_scores_codex":[0.9985377,0.00007567265,0.0004042325,0.0003862859,0.0003896512,0.0002064807],"domain_scores_gemma":[0.9988871,0.00001303307,0.0002422006,0.0002795446,0.0003176119,0.0002605563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0206258,0.07556935,0.3192791,0.0001732278,0.001144947,0.00001503695,0.0273959,0.05135362,0.3628611,0.001703373,0.04421966,0.09565893],"study_design_scores_gemma":[0.3502943,0.03910023,0.3044606,0.0004776162,0.000373702,0.00001783119,0.004977653,0.0008040071,0.1988261,0.007489727,0.09014801,0.003030239],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981214,0.0002347501,0.00004812019,0.0001322233,0.0001986831,0.0007729884,0.00002539268,0.000008855558,0.0004576294],"genre_scores_gemma":[0.9973074,0.000006805059,0.001366968,0.000279759,0.0002471787,0.00005004454,0.0003368539,0.00002728179,0.000377708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3296685,"threshold_uncertainty_score":0.7011278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","authors":[{"name":"Elisabeth I. Heath","is_ca":false},{"name":"Keith C. Bible","is_ca":false},{"name":"Robert E. Martell","is_ca":true},{"name":"Daniel C. Adelman","is_ca":false},{"name":"Patricia LoRusso","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02381757120153434,"gpt":0.3125895757310258,"spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002651473,0.0002332769,0.0005150862,0.000320833,0.00004410428,0.00001171183,0.00006114042,0.00004369171,0.00001940673],"category_scores_gemma":[0.0001732399,0.0001914081,0.00002964168,0.0002742355,0.0003147099,0.0002669471,0.00005670627,0.0001594493,8.600413e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001169715,"about_ca_system_score_gemma":0.0003916759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004618927,"about_ca_topic_score_gemma":0.0002173437,"domain_scores_codex":[0.9979231,0.0000593974,0.0007305066,0.0003297668,0.0007341933,0.0002230624],"domain_scores_gemma":[0.9986618,0.0001585688,0.0004689942,0.0001868535,0.0002221084,0.0003017165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04251535,0.03188136,0.5890997,0.0009556744,0.0007533231,0.0003367946,0.05403939,0.0001630507,0.1017863,0.0002255556,0.00005582016,0.1781877],"study_design_scores_gemma":[0.07007293,0.03068002,0.8636373,0.001475278,0.0002843017,0.00007953712,0.01015793,0.00005233263,0.02121229,0.001830064,0.00009743703,0.0004205737],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984275,0.0001860421,0.00002765666,0.0002217094,0.00003795378,0.001001688,0.00003499659,0.00001656032,0.0000459465],"genre_scores_gemma":[0.9965206,0.000003258761,0.003044,0.000232081,0.00003837705,0.00001808957,0.00004956705,0.00002880197,0.00006521206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2745376,"threshold_uncertainty_score":0.7805396,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035105453","doi":"10.1007/s10637-009-9230-z","title":"A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint-Vincent Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Lung cancer; Overall survival; Oncology; Gastroenterology; Surgery; Chemotherapy","authors":[{"name":"Anne M. Traynor","is_ca":false},{"name":"Ju-Whei Lee","is_ca":false},{"name":"Gerald K. Bayer","is_ca":true},{"name":"John M. Tate","is_ca":false},{"name":"Sachdev Thomas","is_ca":false},{"name":"Miroslaw Mazurczak","is_ca":false},{"name":"David L. Graham","is_ca":false},{"name":"Jill Kolesar","is_ca":false},{"name":"Joan H. Schiller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02281362557493624,"gpt":0.3220910436634508,"spread":0.2992774180885146,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001580816,0.0002564621,0.0005126999,0.00007273249,0.00009163842,0.000007443037,0.0001138816,0.0001142758,0.00002376788],"category_scores_gemma":[0.00008938875,0.0002276831,0.00008764357,0.0001294806,0.0001577332,0.000008495106,0.00005799194,0.0000650295,9.095806e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005129069,"about_ca_system_score_gemma":0.000775368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001159498,"about_ca_topic_score_gemma":0.0001793047,"domain_scores_codex":[0.9985618,0.0001116116,0.0005493723,0.000419346,0.0001681051,0.0001897849],"domain_scores_gemma":[0.9990419,0.00006764376,0.0003168256,0.0001992196,0.000215976,0.0001584828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01180595,0.006233251,0.0006034591,0.00004059555,0.0004193639,0.000009080252,0.008072913,0.000570282,0.9547031,0.00005547956,0.0004057814,0.01708075],"study_design_scores_gemma":[0.2064586,0.1125907,0.0004675574,0.00006837594,0.0002635503,0.000004926788,0.001429115,0.0004338932,0.6718812,0.000237414,0.005767701,0.0003969627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950911,0.002384547,0.00009989388,0.0004635659,0.0001424475,0.001357233,0.0001022256,0.000007830037,0.0003510946],"genre_scores_gemma":[0.9960207,0.000242168,0.001272641,0.0002390359,0.0004177955,0.0001054446,0.0001496842,0.00001640719,0.001536077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2828219,"threshold_uncertainty_score":0.9284648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974638172","doi":"10.1007/s10637-012-9865-z","title":"REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Calgary Laboratory Services; Baker Hughes (Canada); Oncolytics Biotech (Canada); Alberta Cancer Foundation","funders":"Oncolytics Biotech","keywords":"Medicine; Oncolytic virus; Tolerability; Gastroenterology; Toxicity; Internal medicine; Adverse effect; Clinical trial; Cancer; Progressive disease; Surgery; Disease","authors":[{"name":"Don Morris","is_ca":true},{"name":"Xiaolan Feng","is_ca":true},{"name":"Lisa Difrancesco","is_ca":true},{"name":"Kevin Fonseca","is_ca":true},{"name":"Peter Forsyth","is_ca":false},{"name":"Alexander Paterson","is_ca":true},{"name":"Matt Coffey","is_ca":true},{"name":"Brad Thompson","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01760091088536014,"gpt":0.3095962140356946,"spread":0.2919953031503345,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002314392,0.0001292046,0.0001809781,0.00009208065,0.00002995669,0.000005707725,0.0001273196,0.00008347948,0.00004880265],"category_scores_gemma":[0.0001821572,0.0001217167,0.00003875286,0.0001487147,0.0001619757,0.00001843729,0.00003571191,0.0001023159,0.00000442562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003139569,"about_ca_system_score_gemma":0.0007256948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002610292,"about_ca_topic_score_gemma":0.0000372341,"domain_scores_codex":[0.9986925,0.00008584756,0.0003718791,0.0002014813,0.0004244979,0.0002238062],"domain_scores_gemma":[0.9992208,0.00003486429,0.0001827201,0.0002020933,0.0001986182,0.0001608621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1633105,0.001274,0.008060938,0.00003745294,0.00007270841,0.000003679537,0.0002971177,0.0006061375,0.820493,0.0001895826,0.0001837192,0.005471154],"study_design_scores_gemma":[0.0420273,0.01626214,0.0122422,0.0001067546,0.00002541437,0.00001880788,0.00004799553,0.00009519814,0.927928,0.0005108266,0.0003913467,0.0003440211],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9992421,0.0001171412,0.00001174311,0.00007446622,0.00006106769,0.0003535235,0.00003251813,0.000004520714,0.0001029456],"genre_scores_gemma":[0.9974694,0.00001150021,0.001670546,0.00007443941,0.0001587941,0.000009734536,0.0004837025,0.00001929327,0.0001025553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1212832,"threshold_uncertainty_score":0.4963461,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025486703","doi":"10.1007/s10637-005-1157-4","title":"Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Hôpital Notre-Dame; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Nausea; Toxicity; Gastroenterology; Internal medicine; Chemotherapy; Surgery; Progressive disease","authors":[{"name":"D. Scott Ernst","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"M. L. Davis","is_ca":false},{"name":"Reinhard Lohmann","is_ca":false},{"name":"Tara Baetz","is_ca":false},{"name":"Karl Bélanger","is_ca":true},{"name":"Michael Smylie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01162857412818044,"gpt":0.265100812633515,"spread":0.2534722385053345,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001055616,0.0001539498,0.0001740331,0.00006972648,0.0000426606,0.000008884414,0.0001470975,0.00004317455,0.0000555575],"category_scores_gemma":[0.00006446166,0.0001345058,0.00002738872,0.0001884799,0.00008664232,0.00001047388,0.00004893775,0.00006715443,0.000003986279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003915952,"about_ca_system_score_gemma":0.000299007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001566679,"about_ca_topic_score_gemma":0.0002052284,"domain_scores_codex":[0.9988939,0.00006428919,0.0003099934,0.0002872655,0.0002804571,0.0001640505],"domain_scores_gemma":[0.9993787,0.00001764488,0.000147001,0.0002136386,0.0001342753,0.0001087592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004071959,0.02703854,0.5959895,0.0001761405,0.00157098,0.00002617939,0.01810687,0.02779837,0.2720123,0.0007038617,0.0155394,0.03696586],"study_design_scores_gemma":[0.1470445,0.06008006,0.1502598,0.0005794311,0.0006617953,0.00002721178,0.001228817,0.002606366,0.6030514,0.00108794,0.03093698,0.002435685],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989117,0.0002153788,0.00003724227,0.0001989625,0.00002875866,0.0004315971,0.00003110253,0.000008568661,0.000136635],"genre_scores_gemma":[0.9969829,0.00000330521,0.002007005,0.000245695,0.00009635731,0.00003539285,0.0002838779,0.00002081034,0.0003246546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4457297,"threshold_uncertainty_score":0.5484987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","authors":[{"name":"Christopher W. Lee","is_ca":true},{"name":"Karl Bélanger","is_ca":true},{"name":"Sanjay C. Rao","is_ca":true},{"name":"Teresa M. Petrella","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Kerry J. Savage","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Timothy W. Synold","is_ca":false},{"name":"Nancy Wainman","is_ca":true},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08669226906530368,"gpt":0.3826761406183515,"spread":0.2959838715530478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003680908,0.0002295059,0.0008824651,0.0002545761,0.0001204054,0.000005403379,0.0002367055,0.0001088715,0.0002883125],"category_scores_gemma":[0.001880529,0.0001594379,0.0001015269,0.000432499,0.0003162255,0.0001617238,0.00005017375,0.0002495171,0.000001843376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001584861,"about_ca_system_score_gemma":0.005258607,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.05704433,"about_ca_topic_score_gemma":0.09794987,"domain_scores_codex":[0.9959598,0.0009986,0.002126779,0.000309613,0.0003224086,0.0002828278],"domain_scores_gemma":[0.9970725,0.001322588,0.001036967,0.0001817248,0.0003306508,0.00005553877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8573648,0.03491444,0.02498228,0.0001146778,0.004218739,0.00002899327,0.006271905,0.0001759938,0.01293991,0.003043849,0.01103455,0.04490985],"study_design_scores_gemma":[0.7597958,0.04160896,0.1594645,0.0006141416,0.0004283211,0.00001193374,0.001121542,0.00001378858,0.0117735,0.0005981007,0.02381169,0.0007577036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995746,0.0007376855,0.00003945395,0.0002224442,0.001479306,0.001542475,0.0001910758,0.000008240471,0.00003333136],"genre_scores_gemma":[0.9984869,0.00001913191,0.0002649251,0.0002072271,0.00007216056,0.00006998241,0.0002255483,0.00001490443,0.0006392238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1344822,"threshold_uncertainty_score":0.9492349,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W264127248","doi":"10.1023/a:1022976528441","title":"Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pyrogenesis (Canada); BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Pharmacokinetics; Pharmacology; Toxicity; Medicine; DNMT1; Hemoglobin; Chemistry; Methyltransferase; Internal medicine; DNA; Biochemistry","authors":[{"name":"Alison Davis","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Carolyn D. Britten","is_ca":true},{"name":"Nisha Mistry","is_ca":true},{"name":"Henry J. Klamut","is_ca":true},{"name":"Susan D’Aloisio","is_ca":true},{"name":"Martha MacLean","is_ca":true},{"name":"Nancy Wainman","is_ca":false},{"name":"D. Ayers","is_ca":true},{"name":"P. Firby","is_ca":true},{"name":"Jeffrey M. Besterman","is_ca":true},{"name":"Gregory K. Reid","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01797658233807913,"gpt":0.306791163502084,"spread":0.2888145811640048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004389444,0.0001569061,0.0001757413,0.00005385904,0.0002127567,0.00002743806,0.0001774418,0.00007818931,0.00005021132],"category_scores_gemma":[0.0003096485,0.0001218934,0.00006883648,0.0001452131,0.000224835,0.00001045871,0.00007941565,0.0001370703,0.000003166035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001264544,"about_ca_system_score_gemma":0.0002425012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002324926,"about_ca_topic_score_gemma":0.00004322136,"domain_scores_codex":[0.9984943,0.0003888191,0.0002760244,0.0003104334,0.0003122266,0.000218147],"domain_scores_gemma":[0.9993069,0.000065873,0.00009093116,0.0002228927,0.0001039961,0.0002094386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000424361,0.0003671004,0.005617303,0.000009856242,0.00008090595,0.00000944663,0.0004179122,0.00003923417,0.9905332,0.0003176196,0.001955083,0.0006098575],"study_design_scores_gemma":[0.005738851,0.001270329,0.007394942,0.00002812143,0.00006393769,0.00002373817,0.0005614714,0.00005797658,0.9799559,0.001474831,0.003227561,0.0002023968],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981965,0.0001842424,0.00002757177,0.0004728613,0.00006275406,0.000518484,0.00001950005,0.000008917714,0.0005091592],"genre_scores_gemma":[0.9975345,0.00004312407,0.0001384467,0.0006204993,0.00007553698,0.00001613574,0.00002682686,0.00001563616,0.001529323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0105774,"threshold_uncertainty_score":0.497067,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000123112","doi":"10.1023/b:drug.0000026258.02846.1c","title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"National Cancer Institute; McGill University","keywords":"Nausea; Medicine; Gastroenterology; Internal medicine; Vomiting; Diarrhea; Melanoma; Progressive disease; Anorexia; Toxicity; Regimen; Phases of clinical research; Surgery; Chemotherapy; Cancer research","authors":[{"name":"Susan Burdette-Radoux","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"Reinhard Lohmann","is_ca":true},{"name":"Ian Quirt","is_ca":true},{"name":"D. Scott Ernst","is_ca":false},{"name":"Wendy Walsh","is_ca":false},{"name":"Nancy Wainman","is_ca":false},{"name":"A. Dimitrios Colevas","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02107754542709329,"gpt":0.2726131858557945,"spread":0.2515356404287012,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002394354,0.0002001224,0.0002498833,0.0001194402,0.00005688105,0.00001277003,0.0001697,0.0001146502,0.00002930346],"category_scores_gemma":[0.0001871921,0.0001898436,0.0001019104,0.0001717239,0.0001173472,0.00001035861,0.00008966221,0.00009439985,0.00001529574],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003920853,"about_ca_system_score_gemma":0.0009667674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004674412,"about_ca_topic_score_gemma":0.0001882738,"domain_scores_codex":[0.9984835,0.00008338274,0.000533783,0.0003672424,0.0002961625,0.0002358885],"domain_scores_gemma":[0.9992597,0.00002370369,0.0001795137,0.0002621604,0.00007018764,0.0002047053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003463191,0.001360273,0.0001321979,0.00003060083,0.00007115663,0.00005286096,0.0004002691,0.0006293195,0.9872986,0.003960993,0.000653961,0.001946594],"study_design_scores_gemma":[0.0747743,0.002993667,0.000103742,0.00007408797,0.00003683345,0.00002153135,0.00006191953,0.00003251214,0.9106226,0.008556578,0.002479939,0.0002422692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976671,0.0002287831,0.0002571511,0.0005646243,0.0002302335,0.0004554853,0.00008918453,0.00001214749,0.000495323],"genre_scores_gemma":[0.995729,0.00002094194,0.002568599,0.0003034574,0.0003225739,0.00004253558,0.000538587,0.00002050182,0.0004538001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07667597,"threshold_uncertainty_score":0.7741597,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2083983329","doi":"10.1007/s10637-006-6406-7","title":"A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Juravinski Cancer Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Vomiting; Sarcoma; Soft tissue sarcoma; Internal medicine; Adverse effect; Toxicity; Progressive disease; Surgery; Population; Dosing; Gastroenterology; Phases of clinical research; Chemotherapy; Soft tissue; Pathology","authors":[{"name":"Meg Knowling","is_ca":true},{"name":"Martin E. Blackstein","is_ca":true},{"name":"Richard Tozer","is_ca":true},{"name":"V. Bramwell","is_ca":false},{"name":"Janet Dancey","is_ca":false},{"name":"Naomi Dore","is_ca":false},{"name":"S. Matthews","is_ca":false},{"name":"E. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04329356748062302,"gpt":0.3666796670381587,"spread":0.3233860995575357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009308296,0.000241387,0.0006523748,0.00008873212,0.00006332294,0.000009794207,0.0002202557,0.00009022621,0.00005419854],"category_scores_gemma":[0.001251186,0.0001926487,0.00006662666,0.0003395317,0.0002188293,0.00002250311,0.00006035447,0.0001243306,2.521089e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001446168,"about_ca_system_score_gemma":0.006798187,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.06350055,"about_ca_topic_score_gemma":0.2117997,"domain_scores_codex":[0.9967023,0.0003663695,0.001456775,0.0004468817,0.000799359,0.0002282885],"domain_scores_gemma":[0.9981269,0.0002018441,0.0008000607,0.0002081143,0.0005197089,0.0001433436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4543384,0.05399197,0.1114426,0.000615247,0.004243481,0.00007365194,0.001747801,0.1568194,0.09400805,0.00109191,0.04402081,0.07760663],"study_design_scores_gemma":[0.8401645,0.05579471,0.02359534,0.0008094588,0.0007371009,0.000007631925,0.0001942975,0.001183608,0.04330822,0.0009745695,0.03172424,0.001506345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997057,0.0002678231,0.0003229751,0.0001411662,0.000303895,0.001619326,0.0002453723,0.000007101252,0.00003538691],"genre_scores_gemma":[0.9964613,0.000006290367,0.001814718,0.0001997065,0.0003171703,0.0001581668,0.0006234774,0.00002621893,0.0003929889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.385826,"threshold_uncertainty_score":0.9988323,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1991823030","doi":"10.1007/s10637-007-9066-3","title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic carcinoma; Medicine; Internal medicine; Phases of clinical research; Oncology; Deoxycytidine; Chemotherapy; Pancreatic cancer; Cancer","authors":[{"name":"Mary J. MacKenzie","is_ca":false},{"name":"David L. Saltman","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Jennifer A. Low","is_ca":false},{"name":"C. Johnson","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02548080054953892,"gpt":0.338689633946706,"spread":0.313208833397167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081758,0.0002515412,0.0009037169,0.0002622622,0.0001448555,0.000006009343,0.000237076,0.0001392755,0.0000448693],"category_scores_gemma":[0.001328678,0.0001890753,0.00009035806,0.0006407975,0.0007294262,0.0001130061,0.0002432641,0.0003869793,8.078944e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001197119,"about_ca_system_score_gemma":0.001331732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000634274,"about_ca_topic_score_gemma":0.0001028269,"domain_scores_codex":[0.9970922,0.0001641357,0.001068391,0.0004140956,0.0008749221,0.0003861989],"domain_scores_gemma":[0.9978845,0.0006493971,0.0004391326,0.0004492072,0.0002542407,0.0003235169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05188814,0.03070683,0.807254,0.0003733276,0.0005736783,0.0001327331,0.02783751,0.00001411598,0.07324947,0.002235399,0.0006076804,0.005127145],"study_design_scores_gemma":[0.51812,0.04659304,0.4087709,0.000538849,0.0008043469,0.00004603301,0.005051765,0.001209908,0.0161158,0.002152787,0.0001977038,0.0003988071],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938546,0.0002506904,0.0000166089,0.001801261,0.0001405554,0.003052397,0.00003191717,0.00001919707,0.0008327176],"genre_scores_gemma":[0.9981003,0.00002328119,0.0008655711,0.0001505379,0.0001729944,0.00008745143,0.00003429769,0.00002231883,0.0005432349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4662319,"threshold_uncertainty_score":0.7710266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074077730","doi":"10.1007/s10637-008-9190-8","title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Oncology; Regimen; Performance status; Mucositis; Induction chemotherapy; Cancer; Surgery; Histone deacetylase; Biology; Histone","authors":[{"name":"Robert P. Whitehead","is_ca":false},{"name":"Cathryn Rankin","is_ca":false},{"name":"Paulo M. Hoff","is_ca":false},{"name":"Philip J. Gold","is_ca":false},{"name":"Kevin G. Billingsley","is_ca":false},{"name":"Robert Chapman","is_ca":false},{"name":"Lucas Wong","is_ca":false},{"name":"John H. Ward","is_ca":false},{"name":"James L. Abbruzzese","is_ca":false},{"name":"Charles D. Blanke","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0150066062739379,"gpt":0.3032035776085973,"spread":0.2881969713346594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001829581,0.0002449405,0.0003482686,0.0001489232,0.0001264152,0.000007437376,0.0002198608,0.0001275963,0.00002462348],"category_scores_gemma":[0.0002813959,0.0002244947,0.00007925453,0.0003510579,0.0004262691,0.00001862145,0.0001074499,0.0001788975,0.000003794922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001871006,"about_ca_system_score_gemma":0.001837105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009454607,"about_ca_topic_score_gemma":0.001535554,"domain_scores_codex":[0.9978022,0.0002416228,0.0005182873,0.0005456074,0.0005554811,0.0003367823],"domain_scores_gemma":[0.9988625,0.00005411459,0.0002325746,0.0002497772,0.0002315145,0.0003694887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2485002,0.05090727,0.366455,0.000107593,0.0006203289,0.0002337775,0.01004687,0.001739151,0.3037778,0.00007742891,0.00812475,0.009409915],"study_design_scores_gemma":[0.583021,0.07752331,0.207016,0.0002739502,0.0001897344,0.00001492427,0.0004141606,0.0001966527,0.1199306,0.0001326728,0.009888558,0.001398412],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973271,0.0001915012,0.000004604804,0.0001872335,0.00009906318,0.001946303,0.0001438162,0.00002258232,0.00007775119],"genre_scores_gemma":[0.9978607,0.00003140991,0.0003245816,0.00006815167,0.0001934838,0.0004145858,0.0007617009,0.00004796556,0.0002974621],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3345208,"threshold_uncertainty_score":0.9154629,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2014952173","doi":"10.1007/s10637-007-9098-8","title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":81,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Neutropenia; Leukopenia; Chemotherapy; Internal medicine; Gastroenterology; Head and neck squamous-cell carcinoma; Adverse effect; Phases of clinical research; Oncology; Surgery; Head and neck cancer; Radiation therapy","authors":[{"name":"Patricia A. Tang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Stephen Chia","is_ca":true},{"name":"James K. Schwarz","is_ca":true},{"name":"Gregory R. Pond","is_ca":true},{"name":"Caitlin Johnson","is_ca":true},{"name":"A. Dimitrios Colevas","is_ca":false},{"name":"Timothy W. Synold","is_ca":false},{"name":"Lakshmi Vasist","is_ca":false},{"name":"Eric Winquist","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02060612412244646,"gpt":0.2880066215949376,"spread":0.2674004974724912,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001662721,0.0000971511,0.000128844,0.00004578087,0.00003810612,0.000003187099,0.0001212055,0.00003940703,0.000005474591],"category_scores_gemma":[0.00006906346,0.00007114889,0.00003366542,0.0001417888,0.00009319717,0.000003342866,0.00009674988,0.00005958027,2.474215e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008911001,"about_ca_system_score_gemma":0.0002016342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000254089,"about_ca_topic_score_gemma":0.0007660672,"domain_scores_codex":[0.9992241,0.00003974715,0.0003185811,0.0001725496,0.0001343708,0.0001106894],"domain_scores_gemma":[0.9995424,0.00002526937,0.0001358515,0.0001760539,0.00005677816,0.00006361669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004485277,0.003503898,0.0464154,0.0001295206,0.0000292503,0.000004736655,0.003479828,0.000156059,0.9408886,0.0002442088,0.001090381,0.003609618],"study_design_scores_gemma":[0.01549051,0.007218532,0.1015788,0.0000637133,0.00008742405,0.00001885691,0.001655006,0.0004062466,0.8708983,0.0006211671,0.001647821,0.0003136727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990324,0.0003212735,0.00005415913,0.00009957136,0.00005835833,0.0003243077,0.00001933422,0.000001340878,0.00008926641],"genre_scores_gemma":[0.998744,0.000007465935,0.0007647497,0.0001438278,0.00003912402,0.000005198703,0.00002835207,0.000008263204,0.0002590176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06999029,"threshold_uncertainty_score":0.2901368,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2492626689","doi":"10.1007/s10637-016-0377-0","title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Dosing; Tolerability; Trametinib; Medicine; Adverse effect; Rash; MEK inhibitor; Pharmacokinetics; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; MAPK/ERK pathway; Biology","authors":[{"name":"Juneko E. Grilley‐Olson","is_ca":false},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Angelica Fasolo","is_ca":false},{"name":"Mark Cornfeld","is_ca":false},{"name":"Leanne Cartee","is_ca":false},{"name":"A.R. Abdul Razak","is_ca":true},{"name":"Lee-Anne Stayner","is_ca":true},{"name":"Yuhui Wu","is_ca":false},{"name":"Ryan Greenwood","is_ca":false},{"name":"R. Singh","is_ca":false},{"name":"Chul‐min Lee","is_ca":false},{"name":"Johanna C. Bendell","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Gianluca Del Conte","is_ca":false},{"name":"Cristiana Sessa","is_ca":false},{"name":"Jeffrey R. Infante","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007907842871237351,"gpt":0.248194676809058,"spread":0.2402868339378207,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000266923,0.0002051506,0.0001921616,0.00008451389,0.00007030254,0.00001761395,0.0002545374,0.00008311046,0.000008850568],"category_scores_gemma":[0.0001696986,0.0001082942,0.00003738605,0.0003896534,0.000255868,0.00003239587,0.00005860092,0.0001339158,0.000001705928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009413906,"about_ca_system_score_gemma":0.0004161275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006907761,"about_ca_topic_score_gemma":0.0003489409,"domain_scores_codex":[0.9982473,0.0001874722,0.0004143411,0.0003845432,0.0005584452,0.0002079526],"domain_scores_gemma":[0.998961,0.00009370389,0.0003339279,0.0003269015,0.0002075279,0.00007688926],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.004910308,0.006065147,0.4784087,0.00005608032,0.000170992,0.000003724952,0.006464698,0.005052131,0.4810009,0.0004050884,0.001778117,0.01568411],"study_design_scores_gemma":[0.05311109,0.007119237,0.579546,0.0007140508,0.00005467164,0.000002621312,0.0009278695,0.0001632663,0.3560338,0.0009201916,0.0007981262,0.0006091247],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972736,0.00002868213,0.00008754308,0.0013541,0.000109454,0.00107057,0.00002750899,0.000009008972,0.00003951934],"genre_scores_gemma":[0.9990642,0.000001372139,0.0002833061,0.0002258473,0.0001188562,0.0001203844,0.00004926307,0.0000294475,0.0001073442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1249672,"threshold_uncertainty_score":0.4416111,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1976371429","doi":"10.1007/s10637-013-9965-4","title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Gemcitabine; Pharmacokinetics; Medicine; Tolerability; Neutropenia; Pharmacology; Internal medicine; Rash; Gastroenterology; Toxicity; Adverse effect; Chemotherapy","authors":[{"name":"Suzanne Richter","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Eric Xueyu Chen","is_ca":true},{"name":"Blaise Clarke","is_ca":true},{"name":"Ben Tran","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Anastasios Stathis","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Michael Reedijk","is_ca":true},{"name":"Zhuo Chen","is_ca":true},{"name":"Brenda Cohen","is_ca":true},{"name":"Wenjiang Zhang","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"S. Percy Ivy","is_ca":false},{"name":"Malcolm J. Moore","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Elaine McWhirter","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00475852084442618,"gpt":0.2224707915848854,"spread":0.2177122707404593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001071877,0.0001493937,0.0001522539,0.00007590112,0.0000455331,0.000009530535,0.0001218717,0.0000697393,0.00001371242],"category_scores_gemma":[0.00004267209,0.0001034859,0.00001834551,0.0002757828,0.0001411781,0.00002597136,0.0000558502,0.00008736972,0.0000033839],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003334489,"about_ca_system_score_gemma":0.0002402307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001226769,"about_ca_topic_score_gemma":0.0003385308,"domain_scores_codex":[0.9989573,0.0000952065,0.0003027487,0.0002680681,0.0002225475,0.0001541518],"domain_scores_gemma":[0.9994557,0.00001294458,0.0001698568,0.0001641897,0.0001323497,0.00006499403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006539195,0.001816286,0.9539271,0.00001512912,0.0000465848,0.000001256383,0.0007244833,0.001234697,0.03741693,0.00009093314,0.0002419115,0.003830764],"study_design_scores_gemma":[0.01364423,0.001696965,0.9317912,0.00006303101,0.000008541519,0.00000164922,0.0002473985,0.0001131941,0.05169468,0.0004803042,0.00007983811,0.0001789304],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998644,0.00001716652,0.00001642571,0.0002969812,0.00004259041,0.0009171356,0.00001016799,0.000004858249,0.00005067722],"genre_scores_gemma":[0.9984676,7.98025e-7,0.0006202849,0.0001687617,0.00002183909,0.0000768411,0.0005152766,0.00001172495,0.00011684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02213586,"threshold_uncertainty_score":0.4220034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","authors":[{"name":"Srikala S. Sridhar","is_ca":false},{"name":"Eric Winquist","is_ca":false},{"name":"Andrea Eisen","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"Ian F. Tannock","is_ca":true},{"name":"Som D. Mukherjee","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Chantale Blattler","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04450204486330388,"gpt":0.3536828405025805,"spread":0.3091807956392766,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002506981,0.0002191143,0.0005312125,0.0001444598,0.0001400998,0.000006745116,0.0001966482,0.00006353194,0.0004282535],"category_scores_gemma":[0.0003103979,0.0001556888,0.00014039,0.0004538572,0.0003135396,0.00008999289,0.00008162531,0.000306417,0.000002981893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005389652,"about_ca_system_score_gemma":0.001963933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004478533,"about_ca_topic_score_gemma":0.002284975,"domain_scores_codex":[0.9979746,0.00008559709,0.0007658639,0.0002981783,0.0006693095,0.0002064907],"domain_scores_gemma":[0.9987739,0.0001411026,0.0003512115,0.0003656502,0.000165348,0.0002027957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2154208,0.2583049,0.02523774,0.0007695388,0.003967792,0.0001444732,0.1006345,0.001046772,0.3162251,0.005676565,0.01255156,0.06002026],"study_design_scores_gemma":[0.8767185,0.0270406,0.002101446,0.0003052093,0.001307175,0.00002378665,0.0006416313,0.0006949311,0.07976052,0.006078401,0.004984427,0.0003434393],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916713,0.00008820234,0.000007797281,0.004609172,0.0006034026,0.002461282,0.0002870666,0.00001835682,0.0002534576],"genre_scores_gemma":[0.9975341,0.00001179336,0.0003400987,0.0004917294,0.0003988218,0.0002405837,0.00003071304,0.0000256488,0.0009265093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6612976,"threshold_uncertainty_score":0.6770232,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","authors":[{"name":"Shivaani Kummar","is_ca":false},{"name":"James L. Wade","is_ca":false},{"name":"Amit M. Oza","is_ca":true},{"name":"Daniel M. Sullivan","is_ca":false},{"name":"Alice P. Chen","is_ca":false},{"name":"David R. Gandara","is_ca":false},{"name":"Jiuping Ji","is_ca":false},{"name":"Robert J. Kinders","is_ca":false},{"name":"Lihua Wang","is_ca":false},{"name":"Deborah Allen","is_ca":false},{"name":"Geraldine O’Sullivan Coyne","is_ca":false},{"name":"Seth M. Steinberg","is_ca":false},{"name":"James H. Doroshow","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01259685493353731,"gpt":0.2914200369288869,"spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005670162,0.0002982718,0.0008739301,0.000171404,0.0001138284,0.00001384955,0.0001109999,0.0000906733,0.0002242875],"category_scores_gemma":[0.0005532072,0.000160751,0.0001318814,0.0004303414,0.001515938,0.0003092261,0.00004294228,0.0002038021,0.000003375177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002033919,"about_ca_system_score_gemma":0.001072135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007425509,"about_ca_topic_score_gemma":0.00004261001,"domain_scores_codex":[0.9974299,0.0003329073,0.0008252612,0.0004036166,0.0007252316,0.000283079],"domain_scores_gemma":[0.9976749,0.000911526,0.0005734825,0.0002503595,0.0002989171,0.0002908262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625975,0.000584293,0.002086466,0.0000216459,0.0002010149,0.000001766661,0.001449912,0.000004130965,0.0009028901,0.001410367,0.001304065,0.02943587],"study_design_scores_gemma":[0.9782951,0.0007816804,0.004987423,0.0009471746,0.0001324503,0.000004650724,0.00004252095,0.00003416926,0.009729253,0.004441997,0.0003809945,0.000222566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9726589,0.0007396127,0.00007301426,0.02247703,0.0005316421,0.002821297,0.0005315164,0.00003124995,0.0001356768],"genre_scores_gemma":[0.9956955,0.0001990567,0.0008699909,0.001474697,0.0005489763,0.0005129125,0.00007552395,0.00003610938,0.0005872837],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02921331,"threshold_uncertainty_score":0.6555238,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1539780911","doi":"10.1007/s10637-006-9022-7","title":"A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Adverse effect; Rash; Internal medicine; Multiple myeloma; Nausea; Vomiting; Clinical endpoint; Anemia; Gastroenterology; Phases of clinical research; Diarrhea; Pharmacokinetics; Pharmacology; Clinical trial; Oncology","authors":[{"name":"Michael J. Kovacs","is_ca":true},{"name":"Donna Reece","is_ca":false},{"name":"Deborah Marcellus","is_ca":false},{"name":"Ralph M. Meyer","is_ca":false},{"name":"Sarah Mathews","is_ca":false},{"name":"Rui-Ping Dong","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01286201718875107,"gpt":0.2673898610740773,"spread":0.2545278438853262,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000148533,0.0002419682,0.0004628978,0.0003855468,0.00009187735,0.00001058653,0.0000745528,0.00008273699,0.00002176674],"category_scores_gemma":[0.0003492168,0.0001981988,0.00004203253,0.0006943088,0.0002549299,0.000194792,0.00006794954,0.0002265559,0.00000312991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000172027,"about_ca_system_score_gemma":0.0005599082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003132695,"about_ca_topic_score_gemma":0.0004408177,"domain_scores_codex":[0.9978259,0.000098497,0.0005316942,0.0003969348,0.0008563783,0.0002905873],"domain_scores_gemma":[0.9986377,0.0002099187,0.0002526235,0.0002274461,0.0003835174,0.0002887688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005150647,0.01277642,0.9682695,0.00009807378,0.0001821937,0.00003989549,0.002524925,0.00005629569,0.007539871,0.00008134556,0.0004747377,0.00280609],"study_design_scores_gemma":[0.07189522,0.008838983,0.899248,0.0002726273,0.00008096333,0.00000444276,0.0002607942,0.0004493442,0.01839858,0.0003631808,0.00003055421,0.0001573014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977262,0.00009997521,0.000007114664,0.0002399181,0.00002368517,0.001631867,0.0000849953,0.00002200447,0.000164266],"genre_scores_gemma":[0.9973778,0.00000183546,0.001864262,0.00004889603,0.00006511096,0.00007274972,0.0002973583,0.00002983476,0.0002422132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06902149,"threshold_uncertainty_score":0.8082312,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1977529605","doi":"10.1007/s10637-014-0066-9","title":"Phase II trial of vorinostat in advanced melanoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Vorinostat; Clinical endpoint; Medicine; Melanoma; Adverse effect; Nausea; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Randomized controlled trial; Cancer research; Histone deacetylase; Histone; Biology","authors":[{"name":"Naomi B. Haas","is_ca":false},{"name":"Ian Quirt","is_ca":true},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"R. Polintan","is_ca":true},{"name":"Samuel Litwin","is_ca":false},{"name":"Peter D. Adams","is_ca":false},{"name":"Tony McBryan","is_ca":false},{"name":"L. Wang","is_ca":true},{"name":"Lainie P. Martin","is_ca":false},{"name":"Margaret vonMehren","is_ca":false},{"name":"R. Katherine Alpaugh","is_ca":false},{"name":"James Zweibel","is_ca":false},{"name":"Amit M. Oza","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01300294792304773,"gpt":0.2994760520324806,"spread":0.2864731041094329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002720192,0.0001026915,0.000138562,0.00008720784,0.00004325915,0.000005560644,0.0001613648,0.00009162404,0.00002574477],"category_scores_gemma":[0.0005442444,0.0001083414,0.00005725551,0.0001430861,0.0001487996,0.000006189319,0.00008255655,0.00009426964,0.00001176159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001898403,"about_ca_system_score_gemma":0.000362727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006564074,"about_ca_topic_score_gemma":0.00003610051,"domain_scores_codex":[0.9989014,0.00009041202,0.0002934649,0.0002544885,0.0002849122,0.0001753477],"domain_scores_gemma":[0.9994175,0.00004174791,0.00008528701,0.0002332496,0.00007768713,0.000144568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004930331,0.0005958447,0.0002448712,0.00001978073,0.00001904498,0.000001956421,0.0003173411,0.0002982953,0.9630648,0.002430566,0.008904379,0.01917281],"study_design_scores_gemma":[0.05816162,0.00296313,0.000172184,0.00002992549,0.000004130925,0.000003287784,0.00002092339,0.0003055062,0.8603813,0.001879724,0.07589846,0.0001798332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968157,0.00006515478,0.0001335768,0.0006453512,0.0001462795,0.0002332507,0.00002038574,0.000006202658,0.001934096],"genre_scores_gemma":[0.9950412,0.000008320842,0.002278451,0.0001571133,0.0004000496,0.00002313318,0.0002246818,0.00001480947,0.001852276],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1026835,"threshold_uncertainty_score":0.4418035,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025697283","doi":"10.1007/s10637-015-0216-8","title":"The oncolytic virus, pelareorep, as a novel anticancer agent: a review","year":2015,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Virus; Virology; Medicine","authors":[{"name":"Romit Chakrabarty","is_ca":true},{"name":"Hue Tran","is_ca":true},{"name":"Giovanni Selvaggi","is_ca":true},{"name":"Allison Hagerman","is_ca":true},{"name":"Brad Thompson","is_ca":true},{"name":"Matt Coffey","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0784854877160039,"gpt":0.3969353303191214,"spread":0.3184498426031175,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001392173,0.0005267636,0.0008837678,0.00007455956,0.0002257137,0.0001033603,0.001071901,0.0003296908,0.0001299499],"category_scores_gemma":[0.000802878,0.0003715328,0.0005211863,0.0004674614,0.0004588228,0.000006914894,0.0003123357,0.0004755783,0.0007299729],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002021651,"about_ca_system_score_gemma":0.009960625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007517466,"about_ca_topic_score_gemma":0.00009216208,"domain_scores_codex":[0.9966372,0.0003532936,0.0007582789,0.000743,0.001005951,0.0005022638],"domain_scores_gemma":[0.9974876,0.000145257,0.000426908,0.001041339,0.0003457554,0.0005531253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001046426,0.00006662483,5.954327e-7,0.005815764,0.000568056,0.000008586281,0.00003577877,0.000004171895,0.0003794834,0.0009943758,0.2551588,0.7368632],"study_design_scores_gemma":[0.000315138,0.0003809569,3.191322e-7,0.007724334,0.0002866104,0.00007758089,0.000003868929,0.000003880979,0.0001746345,0.001048695,0.9895688,0.0004151436],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002915557,0.9946277,0.00001409094,0.001531893,0.0002258956,0.001440358,0.000161004,0.00002121175,0.001948687],"genre_scores_gemma":[0.000002906106,0.9838077,0.0002259503,0.003225015,0.00117767,0.0003462132,0.001109901,0.0001074416,0.00999724],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.736448,"threshold_uncertainty_score":0.9998736,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2081181781","doi":"10.1007/s10637-007-9103-2","title":"A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Cancer Care Ontario; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Leukocytopenia; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Phases of clinical research; Cancer; Liver function; Pharmacokinetics; Neutropenia; Toxicity; Oncology; Surgery","authors":[{"name":"Jennifer J. Knox","is_ca":true},{"name":"Sharlene Gill","is_ca":true},{"name":"Timothy W. Synold","is_ca":false},{"name":"James Biagi","is_ca":true},{"name":"Pierre Major","is_ca":true},{"name":"Ron Feld","is_ca":true},{"name":"C. Cripps","is_ca":true},{"name":"Nancy Wainman","is_ca":true},{"name":"Elizabeth A. Eisenhauer","is_ca":true},{"name":"Lesley Seymour","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06080585527464875,"gpt":0.3347445557224106,"spread":0.2739387004477618,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005622382,0.0001532704,0.0004159747,0.0000644108,0.00007008913,0.000002603374,0.000180317,0.00004461555,0.000006500899],"category_scores_gemma":[0.000282118,0.0001139052,0.00005045497,0.0002198927,0.0002141355,0.00001047045,0.0001103659,0.0001116448,3.351845e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003476377,"about_ca_system_score_gemma":0.001826153,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03979568,"about_ca_topic_score_gemma":0.04727831,"domain_scores_codex":[0.9978095,0.00034996,0.0009096758,0.0002781897,0.0005321106,0.0001205474],"domain_scores_gemma":[0.9988701,0.00007078372,0.0005420502,0.0001573442,0.0002648673,0.00009489859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005390649,0.005484859,0.9730406,0.00004130498,0.0003729787,0.000003017019,0.001403001,0.0008796272,0.01720921,0.00002642053,0.0007586209,0.0002413288],"study_design_scores_gemma":[0.05462679,0.00550305,0.9189701,0.00008529993,0.0003984641,0.000005729297,0.0006206341,0.001281773,0.01756517,0.0001178288,0.0004674502,0.0003576982],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983708,0.0001453237,0.00001021226,0.00005690656,0.0001098144,0.001161034,0.0001338041,0.00000117635,0.00001088451],"genre_scores_gemma":[0.9994573,0.00001499254,0.0001435938,0.0001570185,0.00005566273,0.00005105537,0.00006489747,0.00001134147,0.00004414401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05408772,"threshold_uncertainty_score":0.9701064,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2093988174","doi":"10.1007/s10637-012-9886-7","title":"The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Abbott Laboratories","keywords":"PARP inhibitor; Irinotecan; Cancer research; Veliparib; Poly ADP ribose polymerase; Olaparib; Oxaliplatin; DNA damage; PARP1; Cancer; Synthetic lethality; DNA repair; Base excision repair; Colorectal cancer; Biology; Medicine; Polymerase; Internal medicine; DNA; Biochemistry","authors":[{"name":"David Davidson","is_ca":true},{"name":"Yunzhe Wang","is_ca":true},{"name":"Raquel Aloyz","is_ca":true},{"name":"Lawrence Panasci","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03616634036575846,"gpt":0.3192929074536835,"spread":0.2831265670879251,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001367419,0.0001917484,0.0002501599,0.00004339476,0.0001484843,0.00001528362,0.0000855712,0.00008931734,0.0002874398],"category_scores_gemma":[0.00003482297,0.0001312724,0.0001179482,0.0001779045,0.0003259856,0.0001429176,0.00001580432,0.00008003834,0.00004288767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004252487,"about_ca_system_score_gemma":0.0007849286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001185911,"about_ca_topic_score_gemma":0.0001050677,"domain_scores_codex":[0.9986218,0.00005588263,0.0003946777,0.0001808944,0.0004484414,0.0002983144],"domain_scores_gemma":[0.9987067,0.0003069384,0.000220433,0.000256176,0.0001629107,0.000346835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001681842,0.00252856,0.1080321,0.0003253111,0.0008634112,0.00001049413,0.01708681,0.0007989014,0.543262,0.02298043,0.2398566,0.06257349],"study_design_scores_gemma":[0.003132131,0.000395622,0.01179686,0.0001578012,0.0001143284,0.00001302931,0.0002571852,0.00009463682,0.6801432,0.001513534,0.3021861,0.0001955128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709805,0.01207084,0.00002065276,0.01247632,0.0008654457,0.0004660412,0.00006534993,0.00006009159,0.002994742],"genre_scores_gemma":[0.9848878,0.001744735,0.001309849,0.00124297,0.002920158,0.0002036019,0.00005540506,0.0000331516,0.007602289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1368812,"threshold_uncertainty_score":0.5353132,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","authors":[{"name":"Mary J. MacKenzie","is_ca":true},{"name":"Holger W. Hirte","is_ca":true},{"name":"Glenwood D. Goss","is_ca":true},{"name":"Maroun Jean","is_ca":true},{"name":"Rakesh Goel","is_ca":true},{"name":"Pierre Major","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Lawrence Panasci","is_ca":true},{"name":"Ian A.J. Lorimer","is_ca":true},{"name":"Gerald Batist","is_ca":true},{"name":"S. Matthews","is_ca":false},{"name":"L. Douglas","is_ca":true},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02695445011454185,"gpt":0.3051791641472074,"spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001451174,0.0003242003,0.0006231703,0.0001937972,0.0001356404,0.00001830675,0.00009248948,0.00006718207,0.0005532606],"category_scores_gemma":[0.0001719223,0.0002441685,0.00009567176,0.0003456838,0.0002992915,0.0003908567,0.00005828535,0.0001945071,0.000007276941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003818092,"about_ca_system_score_gemma":0.0009290089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001658609,"about_ca_topic_score_gemma":0.00092444,"domain_scores_codex":[0.9978165,0.0001113073,0.0005794399,0.0004246012,0.000738771,0.0003293844],"domain_scores_gemma":[0.9988328,0.0001107536,0.0002411664,0.000147251,0.0003153135,0.0003526894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2451715,0.04076638,0.5093464,0.0003568845,0.002189781,0.0000616448,0.03198411,0.0004207831,0.01385469,0.001576636,0.01588459,0.1383866],"study_design_scores_gemma":[0.4908887,0.03158554,0.4430284,0.0005820565,0.000652148,0.000006257829,0.0003557333,0.0005365331,0.0261361,0.0004447028,0.004877002,0.0009068357],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945656,0.0002696049,0.000005218146,0.003127043,0.0002207291,0.001216314,0.0003977292,0.00003590792,0.0001618311],"genre_scores_gemma":[0.9950987,0.00002369446,0.002887387,0.0005438323,0.0004471056,0.0001861972,0.0004349463,0.00003566632,0.0003424872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2457172,"threshold_uncertainty_score":0.9956901,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061189534","doi":"10.1007/s10637-009-9236-6","title":"Cyclin-dependent kinase inhibitors as potential targeted anticancer agents","year":2009,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase; Kinase; Cell cycle; Cyclin; CDK inhibitor; Biology; Cancer research; Drug development; Cell biology; Cell; Drug; Pharmacology; Biochemistry","authors":[{"name":"Iván Díaz-Padilla","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Ignacio Durán","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03175408200627041,"gpt":0.324456682093521,"spread":0.2927026000872506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002664866,0.0008152897,0.001740957,0.0005175071,0.0001392423,0.00007677976,0.000332979,0.0007927679,0.0009135443],"category_scores_gemma":[0.000401835,0.0007687674,0.0009639491,0.0007417665,0.0002404835,0.0001239479,0.0001220424,0.001222064,0.001552291],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008663008,"about_ca_system_score_gemma":0.006749128,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002469451,"about_ca_topic_score_gemma":0.000005919284,"domain_scores_codex":[0.9952192,0.0001809016,0.001286016,0.001031048,0.001691413,0.0005913706],"domain_scores_gemma":[0.9972381,0.00008105086,0.0006748597,0.0006946446,0.000216187,0.001095172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005223051,0.0002242544,0.000004581739,0.00327078,0.0007717841,0.001070848,0.000138601,0.0000965159,0.0002710149,0.000801952,0.07670742,0.91659],"study_design_scores_gemma":[0.001548634,0.0001543237,0.00003305895,0.01326582,0.002225596,0.0005485639,0.000009021115,0.00003480693,0.0003706195,0.001845865,0.9792618,0.000701939],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002745041,0.9916055,0.00006627442,0.001387193,0.001697767,0.001801905,0.0001419586,0.0002152603,0.002809624],"genre_scores_gemma":[0.0002798866,0.9839416,0.001525546,0.002719898,0.003119334,0.00008843806,0.002589513,0.0001899004,0.005545954],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9158881,"threshold_uncertainty_score":0.9999998,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W235826207","doi":"10.1007/s10637-015-0252-4","title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Oncology; Circulating tumor cell; Clinical trial; Cancer; Surgery; Metastasis","authors":[{"name":"Bernhard J. Eigl","is_ca":true},{"name":"Scott North","is_ca":false},{"name":"Eric Winquist","is_ca":true},{"name":"Daygen L. Finch","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true},{"name":"Jean Powers","is_ca":false},{"name":"Jennifer Good","is_ca":true},{"name":"Mansi Sharma","is_ca":false},{"name":"Jeremy A. Squire","is_ca":true},{"name":"Jenny Bazov","is_ca":false},{"name":"Tamara Jamaspishvili","is_ca":true},{"name":"Michael Cox","is_ca":false},{"name":"Penelope A. Bradbury","is_ca":false},{"name":"Elizabeth A. Eisenhauer","is_ca":false},{"name":"K. N.","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08111566582937407,"gpt":0.401434337902309,"spread":0.320318672072935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002822546,0.0001884039,0.0003640275,0.00009302223,0.0001129411,0.00002476102,0.0002515805,0.0001081763,0.000005464299],"category_scores_gemma":[0.001521937,0.0001327881,0.00006876088,0.0003958686,0.000221171,0.00001855732,0.0001737239,0.0002568412,0.000002059508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001083817,"about_ca_system_score_gemma":0.001672288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00100137,"about_ca_topic_score_gemma":0.002723688,"domain_scores_codex":[0.9959255,0.001341575,0.001069732,0.0004752923,0.0009716199,0.0002163039],"domain_scores_gemma":[0.9983929,0.00007929491,0.0004602209,0.0004082819,0.0004091844,0.0002501602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01394462,0.03117112,0.8105518,0.0000513536,0.0004412103,0.00001577097,0.01834254,0.0006422269,0.09898849,0.00004779778,0.01946095,0.006342114],"study_design_scores_gemma":[0.1996208,0.1028353,0.5589681,0.0004667177,0.0003289777,0.000003905838,0.01123129,0.0001583947,0.1189473,0.0005033707,0.005587893,0.001348037],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966606,0.00007462776,0.000001814702,0.0003149862,0.0002081112,0.002620531,0.00008045782,0.000006795395,0.00003204757],"genre_scores_gemma":[0.9988911,0.000002354461,0.0001054423,0.00007760611,0.0003151988,0.0001731134,0.0001262435,0.00002379889,0.0002851871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2515838,"threshold_uncertainty_score":0.5414941,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","authors":[{"name":"Andrew J. Armstrong","is_ca":false},{"name":"Ravit Geva","is_ca":false},{"name":"Hyun Cheol Chung","is_ca":false},{"name":"Charlotte Lemech","is_ca":false},{"name":"Wilson H. Miller","is_ca":true},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Jong Seok Lee","is_ca":false},{"name":"Frank Tsai","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Tae Min Kim","is_ca":false},{"name":"Christian Rolfo","is_ca":false},{"name":"Vincent L. Giranda","is_ca":false},{"name":"Yixin Ren","is_ca":false},{"name":"Fang Liu","is_ca":false},{"name":"Bhargava Kandala","is_ca":false},{"name":"Tomoko Freshwater","is_ca":false},{"name":"Judy S. Wang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01262812956067111,"gpt":0.3092178169209199,"spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006799052,0.0002077637,0.000553653,0.0003891884,0.00004297386,0.00007224325,0.00007845514,0.00008333592,0.0001133215],"category_scores_gemma":[0.0001867535,0.00016645,0.0001162297,0.0009002005,0.0002574423,0.000242876,0.00001121757,0.0002940835,0.00001483434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003621762,"about_ca_system_score_gemma":0.002004729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006940753,"about_ca_topic_score_gemma":0.0001749941,"domain_scores_codex":[0.9981795,0.0001507435,0.0006245434,0.0003609792,0.0004416776,0.0002425601],"domain_scores_gemma":[0.9992317,0.0003461459,0.0001029652,0.0001357786,0.00005924534,0.0001241623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9712556,0.0004260075,0.00009174923,0.0001139562,0.0001307317,0.0001389069,0.001934678,0.00007730411,0.01109606,0.004893171,0.0009870504,0.008854807],"study_design_scores_gemma":[0.9756379,0.0009022235,0.0003421688,0.001185005,0.00005494964,0.00009218218,0.00009443353,0.005851313,0.005805613,0.007830329,0.001978552,0.0002253729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867374,0.001095603,0.0001586267,0.007933629,0.0002767289,0.002045927,0.00001490145,0.0001012212,0.00163601],"genre_scores_gemma":[0.9960834,0.00006552525,0.000988243,0.0009345713,0.0002200482,0.0002439786,0.0002872996,0.00003248121,0.001144417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009346083,"threshold_uncertainty_score":0.6787636,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2073021016","doi":"10.1007/s10637-005-0793-z","title":"Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Medicine; Carcinoma; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","authors":[{"name":"Philip Shaheen","is_ca":false},{"name":"Walter M. Stadler","is_ca":false},{"name":"Paul Elson","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Eric Winquist","is_ca":true},{"name":"Ronald M. Bukowski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01972554583441963,"gpt":0.2647082686783908,"spread":0.2449827228439712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237202,0.0001785127,0.0003588412,0.0001028641,0.00005200939,0.000003764133,0.00009525618,0.00002728156,0.00004093217],"category_scores_gemma":[0.00007645502,0.0001024464,0.00003571477,0.0003438049,0.0001872861,0.00009403298,0.00006260504,0.000129859,0.000001368279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001004973,"about_ca_system_score_gemma":0.0005324993,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001772747,"about_ca_topic_score_gemma":0.0001330577,"domain_scores_codex":[0.9983975,0.00008941016,0.000502183,0.0002481966,0.0006109291,0.0001517993],"domain_scores_gemma":[0.9990441,0.0001329418,0.0002396409,0.0002636054,0.0001526937,0.0001670797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0291619,0.02996276,0.8650814,0.0003339326,0.000405919,0.00005483205,0.01991036,0.008009199,0.008451198,0.0002406116,0.0005313801,0.03785653],"study_design_scores_gemma":[0.0782453,0.01223553,0.8903963,0.0001811686,0.0002820585,0.000007053627,0.0003563184,0.0002090866,0.01775473,0.00006159016,0.0001351398,0.0001357401],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977105,0.00008036974,0.000009070829,0.000489586,0.0000173199,0.001484495,0.00001924421,0.000006519659,0.0001829422],"genre_scores_gemma":[0.9943382,0.000001252403,0.005008065,0.0001584171,0.00001844383,0.0000175488,0.00003392791,0.0000172102,0.0004069482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0490834,"threshold_uncertainty_score":0.4177644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015941325","doi":"10.1007/s10637-010-9494-3","title":"Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Cisplatin; Cytoplasm; Liposome; Chemistry; DNA; Cancer cell; Intracellular; Cytotoxicity; Cancer research; Pharmacology; Molecular biology; Biochemistry; Biology; Colorectal cancer; Cancer; Chemotherapy; In vitro","authors":[{"name":"Thititip Tippayamontri","is_ca":true},{"name":"Rami Kotb","is_ca":true},{"name":"Benoît Paquette","is_ca":true},{"name":"Léon Sanche","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02019884188833627,"gpt":0.2418739762223202,"spread":0.221675134333984,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002011478,0.0001346566,0.0002305265,0.00004510815,0.00008577827,0.00002210954,0.00003023432,0.00009532744,0.0000671372],"category_scores_gemma":[0.00007743539,0.0001061994,0.00002380249,0.00007172475,0.0001775954,0.0001482685,0.00003732053,0.0001465527,5.652364e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001989713,"about_ca_system_score_gemma":0.00009295631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006926689,"about_ca_topic_score_gemma":0.0004605994,"domain_scores_codex":[0.9991887,0.0000314457,0.0003076771,0.0001991048,0.0001541284,0.0001189336],"domain_scores_gemma":[0.9994987,0.0001192623,0.0001164028,0.00007456572,0.00005576004,0.0001353167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00006216355,0.00002223659,0.05784322,0.00009002427,0.00001076514,5.293976e-7,0.001052951,0.000003863441,0.9337219,0.005434594,0.00005093495,0.001706803],"study_design_scores_gemma":[0.0009440659,0.0001077538,0.4503146,0.0001010254,0.00002625413,0.00001344778,0.0001139596,0.003181999,0.5397429,0.004772841,0.0005628137,0.0001183677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982363,0.0004847254,0.00002218323,0.0004637652,0.00004582607,0.0002471745,0.00005589381,0.00001161198,0.0004324962],"genre_scores_gemma":[0.9987333,0.00002749475,0.0007443586,0.00006080232,0.0001029591,0.00001228498,0.0001444358,0.00001098177,0.0001633493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.393979,"threshold_uncertainty_score":0.4330688,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2072016597","doi":"10.1007/s10637-011-9700-y","title":"Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Jurkat cells; Cell culture; Cell growth; Chemistry; Growth inhibition; Cell biology; Kinase; Flow cytometry; Cancer research; Molecular biology; Biology; Biochemistry; Immunology; T cell; Genetics","authors":[{"name":"Darya Habibi","is_ca":true},{"name":"Nadya Ogloff","is_ca":true},{"name":"Reza B. Jalili","is_ca":true},{"name":"Arla Yost","is_ca":true},{"name":"Andrew P. Weng","is_ca":true},{"name":"Aziz Ghahary","is_ca":true},{"name":"Christopher J. Ong","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02351559366078806,"gpt":0.2322449968493194,"spread":0.2087294031885313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001564709,0.0001843528,0.0002319023,0.0001334692,0.00003704624,0.000009008582,0.0002404229,0.0001595037,0.00005342065],"category_scores_gemma":[0.00009530523,0.0001860637,0.0001192181,0.0002434199,0.0001672557,0.00001106354,0.00008891834,0.00009488554,0.000007141255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007179008,"about_ca_system_score_gemma":0.0009525543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009040808,"about_ca_topic_score_gemma":0.00002766714,"domain_scores_codex":[0.998663,0.00004828718,0.0005115841,0.0003479485,0.0002132994,0.0002158958],"domain_scores_gemma":[0.9990503,0.00002545044,0.0002835188,0.0003224536,0.0001780657,0.000140242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002252079,0.00009705598,0.006593069,0.00003523166,0.0001565023,0.000002011662,0.001174857,0.0001670479,0.9873552,0.00108758,0.001710743,0.001395476],"study_design_scores_gemma":[0.0009285233,0.0001550111,0.008314678,0.0001163405,0.00005782495,0.000007598241,0.0001787762,0.0002181365,0.9879107,0.001573426,0.0003346554,0.0002042799],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997287,0.0003876944,0.0006259031,0.0001838294,0.00008340915,0.0001914888,0.0001003952,0.000006952538,0.001133299],"genre_scores_gemma":[0.9954847,0.00009268831,0.003411258,0.0005040569,0.00009032662,0.00005100381,0.00009742288,0.00002571591,0.0002428598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002785355,"threshold_uncertainty_score":0.7587457,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2013709636","doi":"10.1007/s10637-013-0001-5","title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Internal medicine; Pharmacokinetics; Pharmacology; Neutropenia; Rash; Gastroenterology; Oncology; Toxicity","authors":[{"name":"Iván Díaz-Padilla","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Blaise Clarke","is_ca":true},{"name":"Brenda Cohen","is_ca":true},{"name":"Michael Reedjik","is_ca":true},{"name":"Tong Zhang","is_ca":true},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"S. Percy Ivy","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Albiruni Abdul Razak","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Irene Braña","is_ca":true},{"name":"Monika Wizemann","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01450826635240509,"gpt":0.2992024669756905,"spread":0.2846942006232854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001069464,0.00018017,0.0003446003,0.0001963092,0.00004659966,0.00001178948,0.00004648897,0.00004630101,0.00004019659],"category_scores_gemma":[0.00006853943,0.0001485132,0.00001797511,0.0003092165,0.0001172639,0.000250875,0.00002658414,0.0001403961,0.00001041201],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002345087,"about_ca_system_score_gemma":0.0004682025,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001043111,"about_ca_topic_score_gemma":0.00007208271,"domain_scores_codex":[0.9983549,0.0000550941,0.0005081844,0.0002998556,0.0005569581,0.0002250241],"domain_scores_gemma":[0.9988939,0.00007575216,0.0002333467,0.0001876083,0.0002340924,0.0003752988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008844258,0.007212808,0.9689308,0.0002051969,0.00006213302,0.00001452797,0.004362621,0.00009620615,0.0003675644,0.0001679361,0.0005152908,0.01718044],"study_design_scores_gemma":[0.05591399,0.009598765,0.9297264,0.0004544404,0.00005454062,0.000004502254,0.0006647162,0.0004531298,0.001321505,0.001585115,0.00005184529,0.0001710762],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959961,0.00009461222,0.000003098665,0.001290518,0.00005801461,0.002435575,0.00001707568,0.00002594345,0.00007911129],"genre_scores_gemma":[0.9976983,0.000003249088,0.001330262,0.0004797086,0.00004651627,0.0002121146,0.0001277578,0.00002253176,0.00007955336],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05502957,"threshold_uncertainty_score":0.6056192,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2795799317","doi":"10.1007/s10637-018-0591-z","title":"A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Pharmacodynamics; Adverse effect; Internal medicine; Gastroenterology; Nausea; Pharmacology","authors":[{"name":"Carol Aghajanian","is_ca":false},{"name":"Katherine M. Bell‐McGuinn","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Lee-Ann Stayner","is_ca":true},{"name":"Jennifer J. Wheler","is_ca":false},{"name":"David S. Hong","is_ca":false},{"name":"Carla Kurkjian","is_ca":false},{"name":"Shubham Pant","is_ca":false},{"name":"Ademi Santiago-Walker","is_ca":false},{"name":"Jennifer Gauvin","is_ca":false},{"name":"Joyce Antal","is_ca":false},{"name":"Joanna Opalinska","is_ca":false},{"name":"Shannon R. Morris","is_ca":false},{"name":"Jeffrey R. Infante","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02342681837866611,"gpt":0.3401203968094243,"spread":0.3166935784307582,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005862497,0.0002777612,0.0002685083,0.00005795153,0.0001801731,0.00007307207,0.0007981004,0.00005044144,0.00002950253],"category_scores_gemma":[0.0001910452,0.0001889148,0.00002875086,0.00040958,0.0008578848,0.00002654442,0.0007977242,0.0002077709,0.000003503833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006617132,"about_ca_system_score_gemma":0.0006443563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003896779,"about_ca_topic_score_gemma":0.0004412818,"domain_scores_codex":[0.9978618,0.0002662175,0.0005419686,0.0005516738,0.0004804231,0.0002978868],"domain_scores_gemma":[0.9986476,0.00005573855,0.0002567384,0.0004746482,0.0003137299,0.0002515109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004460123,0.005465996,0.5012798,0.00009019267,0.0004718125,0.000005831549,0.007031977,0.006051674,0.4591841,0.0005950013,0.01065928,0.004704247],"study_design_scores_gemma":[0.07881361,0.01113077,0.09441389,0.000496969,0.0003022256,0.00001039271,0.0007489061,0.006014662,0.789213,0.003027844,0.01412281,0.001704907],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959791,0.00004542584,0.00005329375,0.001723082,0.0002592793,0.001609423,0.0001878553,0.000009223989,0.0001333359],"genre_scores_gemma":[0.9949732,0.000002880631,0.001077258,0.003242797,0.0002932766,0.00005411295,0.00006581905,0.00003841411,0.0002522161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4068659,"threshold_uncertainty_score":0.770372,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2050197847","doi":"10.1007/s10637-014-0159-5","title":"A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Doxorubicin; Pharmacokinetics; Pantoprazole; Medicine; Pharmacology; Chemotherapy; Internal medicine","authors":[{"name":"Irene Braña","is_ca":true},{"name":"Alberto Ocaña","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Christine Haines","is_ca":true},{"name":"Carol Lee","is_ca":true},{"name":"Sarah F. Douglas","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Ian F. Tannock","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01229624724605933,"gpt":0.2958925228316514,"spread":0.283596275585592,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004980012,0.0001128254,0.000240242,0.0001257216,0.000009770573,0.000003071809,0.00007040311,0.00005788173,0.000005541305],"category_scores_gemma":[0.00004623285,0.0001028052,0.00001753869,0.0001794693,0.0001168441,0.00001575948,0.0000175113,0.00004822455,4.775477e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000201889,"about_ca_system_score_gemma":0.0002968876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001520811,"about_ca_topic_score_gemma":0.00009529979,"domain_scores_codex":[0.9986954,0.0001021532,0.0004632214,0.0001867836,0.0004589042,0.00009353448],"domain_scores_gemma":[0.9989994,0.00002846891,0.0004675246,0.0001332401,0.0003277701,0.00004364589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.007294083,0.0007213784,0.002258781,0.00007504634,0.00002916719,5.227301e-8,0.0007495427,0.003262246,0.9651709,0.0009824497,0.000006594305,0.01944974],"study_design_scores_gemma":[0.07770293,0.004321359,0.007517789,0.0001609363,0.00005198894,2.918345e-7,0.00007698236,0.002652505,0.9056384,0.001723876,0.00004464816,0.0001082864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984187,0.0000752171,0.0006184783,0.00006038515,0.00003161313,0.0006863398,0.00002440959,0.0000014296,0.00008345598],"genre_scores_gemma":[0.9982168,0.00002247797,0.001440789,0.00003932104,0.00002477771,0.0000216116,0.0002127077,0.00001205725,0.000009429432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07040885,"threshold_uncertainty_score":0.4192275,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000023204","doi":"10.1007/s10637-010-9570-8","title":"A phase I study of temsirolimus and metformin in advanced solid tumours","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Temsirolimus; Metformin; Medicine; Internal medicine; Maximum tolerated dose; Toxicity; Cancer; Limiting; Gastroenterology; Discovery and development of mTOR inhibitors","authors":[{"name":"Mary J. MacKenzie","is_ca":true},{"name":"Scott Ernst","is_ca":true},{"name":"Craig A. Johnson","is_ca":true},{"name":"Eric Winquist","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01204302114974114,"gpt":0.3080307372402999,"spread":0.2959877160905588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001853168,0.00011748,0.0001434938,0.00006818808,0.00002833096,0.000009698315,0.000133398,0.00007950053,0.00001484534],"category_scores_gemma":[0.0001725084,0.0001191592,0.00002506249,0.0001107641,0.000123795,0.000008596813,0.00005734123,0.0001335399,0.000001567079],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008762888,"about_ca_system_score_gemma":0.0002490486,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001272899,"about_ca_topic_score_gemma":0.000179875,"domain_scores_codex":[0.9991359,0.00002806411,0.0002550201,0.0002641356,0.0001756035,0.0001413124],"domain_scores_gemma":[0.9994805,0.00003031311,0.0001108104,0.0001911559,0.0000635884,0.0001236011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008733035,0.0002996964,0.008949162,0.00000845322,0.00002141075,0.000002920409,0.0005885533,0.0002120784,0.9859861,0.0002354097,0.0003374542,0.00327143],"study_design_scores_gemma":[0.01024048,0.00160126,0.01377051,0.00003736444,0.00003116416,0.00002965654,0.000594378,0.0004548893,0.9633265,0.004617534,0.00492597,0.0003702714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990134,0.0001684148,0.00002424339,0.0001542357,0.0001384906,0.000233002,0.00001471258,0.00000670324,0.0002468018],"genre_scores_gemma":[0.9971424,0.000008189826,0.002193801,0.0001843756,0.000180716,0.0000290537,0.0000356428,0.00001508032,0.0002106812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02265958,"threshold_uncertainty_score":0.4859171,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089379119","doi":"10.1007/s10637-010-9626-9","title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"RAD51; Molecular biology; DNA-PKcs; DNA damage; Irinotecan; Comet assay; Cancer research; DNA repair; DNA; Chemistry; Homologous recombination; DNA ligase; Biology; Colorectal cancer; Cancer; Biochemistry; Genetics","authors":[{"name":"David Davidson","is_ca":true},{"name":"Yannick Coulombe","is_ca":true},{"name":"Verónica L. Martínez‐Marignac","is_ca":true},{"name":"Lilian Amrein","is_ca":true},{"name":"Jeremy Grenier","is_ca":true},{"name":"Keira Hodkinson","is_ca":true},{"name":"Jean‐Yves Masson","is_ca":true},{"name":"Raquel Aloyz","is_ca":true},{"name":"Lawrence Panasci","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0160094944983551,"gpt":0.2261960770657665,"spread":0.2101865825674114,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109539,0.0001008106,0.0001052641,0.00005100456,0.00002006574,0.000004797839,0.00008941319,0.0001078786,0.00002825534],"category_scores_gemma":[0.00002276079,0.0001061427,0.00003043739,0.00008639279,0.000116653,0.000005594734,0.00006533804,0.00005804628,0.000002234478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001601351,"about_ca_system_score_gemma":0.0002152448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006411276,"about_ca_topic_score_gemma":0.0001445178,"domain_scores_codex":[0.999289,0.00002907926,0.0002051282,0.0002239384,0.0001231737,0.0001296367],"domain_scores_gemma":[0.9996256,0.00001260183,0.00009122908,0.0001192537,0.00004483157,0.0001064898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00002209288,0.00002523828,0.002277395,0.00001670764,0.0000135981,0.000001469867,0.0004303377,0.00008938087,0.9945615,0.0009675699,0.0005134288,0.001081271],"study_design_scores_gemma":[0.0003326931,0.00007677864,0.001531182,0.00004584214,0.000007453055,0.000001989537,0.00006169316,0.000119035,0.9933842,0.002949201,0.001373365,0.0001165587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986874,0.000331607,0.00006489465,0.0001252008,0.0001422587,0.0001062956,0.00001275664,0.000007639213,0.0005219261],"genre_scores_gemma":[0.9939632,0.00007523028,0.00520932,0.0002509764,0.0001094621,0.00001412085,0.00001970315,0.00001457912,0.0003434178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005144426,"threshold_uncertainty_score":0.4328375,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2337001617","doi":"10.1007/s10637-016-0351-x","title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Irinotecan; Medicine; Tolerability; Internal medicine; Regimen; Oncology; Neutropenia; PARP inhibitor; Colorectal cancer; Cancer; Chemotherapy; Adverse effect","authors":[{"name":"Eric X. Chen","is_ca":true},{"name":"Derek J. Jonker","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Karyn McKeever","is_ca":true},{"name":"Deborah S. Keller","is_ca":false},{"name":"Julie Wells","is_ca":false},{"name":"Linda Hagerman","is_ca":false},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03639334982599422,"gpt":0.3302634596488522,"spread":0.293870109822858,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003363155,0.0001746368,0.0004792003,0.0003031239,0.00005355698,0.00001140658,0.00007355631,0.00007604884,0.0002848827],"category_scores_gemma":[0.0001463764,0.0001210356,0.00002893542,0.0003471659,0.0002226266,0.0001480951,0.00001413501,0.000121385,0.000002298914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005828143,"about_ca_system_score_gemma":0.002282244,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1690231,"about_ca_topic_score_gemma":0.2089449,"domain_scores_codex":[0.9983245,0.0001289841,0.0005249812,0.0003158844,0.0004660138,0.0002395968],"domain_scores_gemma":[0.99874,0.0001990136,0.0002657674,0.0001352312,0.0001734633,0.0004865628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001613795,0.0008042946,0.9692804,0.00002587221,0.0001780237,0.000006566498,0.003229273,0.00001543185,0.003150508,0.0003103803,0.001539677,0.01984583],"study_design_scores_gemma":[0.0801587,0.003067754,0.9063354,0.0008763774,0.0001160636,0.000002919999,0.0002680258,0.00001483699,0.006486803,0.0008607513,0.001534528,0.000277865],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945475,0.0001696408,0.000006775191,0.003404076,0.0001273692,0.001263995,0.0003568343,0.00001547025,0.0001082645],"genre_scores_gemma":[0.9984556,0.00003392952,0.000174637,0.0007529826,0.0001760105,0.0002560842,0.00003570909,0.00002333085,0.00009169219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07854491,"threshold_uncertainty_score":0.8365104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2033997665","doi":"10.1007/s10637-011-9650-4","title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Clinical endpoint; Adenocarcinoma; Oncology; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","authors":[{"name":"Helen Mackay","is_ca":true},{"name":"H. Au","is_ca":true},{"name":"Elaine McWhirter","is_ca":true},{"name":"Thierry Alcindor","is_ca":true},{"name":"A. Järvi","is_ca":true},{"name":"K. MacAlpine","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Amit M. Oza","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03554854809381155,"gpt":0.2814283974656747,"spread":0.2458798493718632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003922274,0.0003330385,0.0006423654,0.0002749256,0.0001720741,0.0000116191,0.0003136339,0.00006786926,0.0002561592],"category_scores_gemma":[0.0009063657,0.0001783693,0.000213385,0.001314928,0.0004825486,0.0002457219,0.0001766285,0.0003052132,0.000002597167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001556323,"about_ca_system_score_gemma":0.001875981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001892624,"about_ca_topic_score_gemma":0.00007314075,"domain_scores_codex":[0.9967324,0.0001966765,0.001149389,0.0004110902,0.001165819,0.0003445938],"domain_scores_gemma":[0.9978394,0.0001870415,0.0009596641,0.0005210151,0.0002749846,0.0002178897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9489641,0.0127134,0.01804489,0.0002275367,0.0003374415,0.00002638197,0.00284542,0.00007627487,0.0004065413,0.0004701645,0.004282854,0.01160504],"study_design_scores_gemma":[0.9144779,0.0331317,0.04712744,0.0004250826,0.0008449854,0.00001123596,0.0003431901,0.000176039,0.002524949,0.0003387239,0.0003709672,0.0002277919],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937251,0.00003939744,0.0001220438,0.0009113271,0.0007641737,0.004206497,0.00007113472,0.00002492924,0.0001353472],"genre_scores_gemma":[0.9941753,0.000003320651,0.00294829,0.0005281306,0.0002911736,0.0001634119,0.00007176193,0.00003246032,0.001786214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03448616,"threshold_uncertainty_score":0.7273691,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047528221","doi":"10.1007/s10637-010-9611-3","title":"A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Essar Steel Algoma (Canada); BC Cancer Agency; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Clinical endpoint; Oncology; Progressive disease; Phases of clinical research; Stage (stratigraphy); Deoxycytidine; Cancer; Chemotherapy; Clinical trial; Gastroenterology","authors":[{"name":"Daniel J. Renouf","is_ca":true},{"name":"Malcolm J. Moore","is_ca":true},{"name":"David W. Hedley","is_ca":true},{"name":"Sharlene Gill","is_ca":true},{"name":"Derek J. Jonker","is_ca":true},{"name":"Eric X. Chen","is_ca":true},{"name":"David Walde","is_ca":true},{"name":"Rakesh Goel","is_ca":true},{"name":"Bernadette Southwood","is_ca":true},{"name":"Isabelle Gauthier","is_ca":false},{"name":"Wendy Walsh","is_ca":false},{"name":"L. McIntosh","is_ca":false},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02456104693955328,"gpt":0.3483358976497588,"spread":0.3237748507102055,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004211357,0.0001452287,0.0004144907,0.0002106652,0.00007669297,0.000006377648,0.000149564,0.00008778912,0.0001247858],"category_scores_gemma":[0.0005569608,0.00009805788,0.00002900623,0.0007636548,0.0002802027,0.0001204846,0.00005867257,0.0005071905,0.000003944498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001190459,"about_ca_system_score_gemma":0.001785946,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001950813,"about_ca_topic_score_gemma":0.003736025,"domain_scores_codex":[0.99833,0.000110659,0.0004715206,0.0002581943,0.0006091644,0.0002204509],"domain_scores_gemma":[0.9989173,0.0002789124,0.0001782292,0.0002890491,0.0001894037,0.0001471152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007390593,0.004306965,0.9554579,0.00006173577,0.0000524349,0.0000123489,0.006642123,0.00006477648,0.02746875,0.001612125,0.0004190612,0.003162759],"study_design_scores_gemma":[0.03422645,0.002800335,0.953939,0.0004075041,0.00009138326,0.00001424888,0.001047691,0.001910995,0.002814218,0.002347535,0.0002645405,0.0001361473],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917998,0.00005674762,0.000004145093,0.005567965,0.00009264128,0.001574463,0.000008208947,0.00001325769,0.0008827735],"genre_scores_gemma":[0.9969423,0.000007995916,0.001321997,0.0003191806,0.0000908994,0.0002652692,0.00002177328,0.00001595267,0.001014627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03348739,"threshold_uncertainty_score":0.3998685,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2597378792","doi":"10.1007/s10637-017-0450-3","title":"A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Quebec Rehabilitation Research Network","funders":"University of Minnesota","keywords":"Carboplatin; Cetuximab; Medicine; Clinical endpoint; Paclitaxel; Internal medicine; Oncology; Adverse effect; Phases of clinical research; Chemotherapy; Lung cancer; Randomized controlled trial; Cancer; Colorectal cancer; Cisplatin","authors":[{"name":"Michael Thomas","is_ca":false},{"name":"Parvis Sadjadian","is_ca":false},{"name":"Jens Kollmeier","is_ca":false},{"name":"Jamie Lowe","is_ca":false},{"name":"Paulette Mattson","is_ca":false},{"name":"J. Richard Trout","is_ca":false},{"name":"Michele Gargano","is_ca":false},{"name":"Myra L. Patchen","is_ca":false},{"name":"Richard M. Walsh","is_ca":false},{"name":"Martin Béliveau","is_ca":true},{"name":"Jean‐Francois Marier","is_ca":true},{"name":"Nandita Bose","is_ca":false},{"name":"Keith Gorden","is_ca":false},{"name":"Folker Schneller","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02367520973491477,"gpt":0.344474568354692,"spread":0.3207993586197773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007567824,0.0001907361,0.0005531305,0.0001287703,0.0002439537,0.00006687944,0.0001558488,0.00003852609,0.00002087626],"category_scores_gemma":[0.0001581495,0.0001233856,0.00002070421,0.0001763468,0.000297129,0.000275574,0.0000976731,0.0001767644,2.476667e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007825721,"about_ca_system_score_gemma":0.0003428467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001244184,"about_ca_topic_score_gemma":0.0003151624,"domain_scores_codex":[0.9984894,0.0001480521,0.0004635327,0.000336757,0.0004043489,0.0001578776],"domain_scores_gemma":[0.9986503,0.0002360545,0.0004947672,0.000276084,0.0002169069,0.0001259461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2274284,0.01158134,0.7100926,0.0002081667,0.0004642221,0.000007714341,0.01645119,0.0002780306,0.006606804,0.0001096874,0.00005328792,0.02671858],"study_design_scores_gemma":[0.7309299,0.00201666,0.251861,0.001111315,0.0001878604,6.199014e-7,0.0002988298,0.01236262,0.001039085,0.00004599484,0.000003139033,0.0001430437],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939195,0.00008256365,0.00003396127,0.002571407,0.00001088732,0.003228585,0.00001646338,0.000006255398,0.0001304108],"genre_scores_gemma":[0.9971928,0.00002488092,0.001908502,0.0005083649,0.00001838817,0.0001267466,0.00005418824,0.00001880475,0.0001473512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5035015,"threshold_uncertainty_score":0.503152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","authors":[{"name":"Nicolas Penel","is_ca":false},{"name":"Corinne Delcambre","is_ca":false},{"name":"Xavier Durando","is_ca":false},{"name":"Stéphanie Clisant","is_ca":false},{"name":"Mohamed Hebbar","is_ca":false},{"name":"Sylvie Négrier","is_ca":false},{"name":"Charles Fournier","is_ca":false},{"name":"Nicolás Isambert","is_ca":false},{"name":"Frédéric Mascarelli","is_ca":false},{"name":"F. Mouriaux","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04069337693991506,"gpt":0.3313887372190749,"spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005252209,0.0004901682,0.001081346,0.0003442171,0.0002349478,0.00001153272,0.0002184117,0.00027642,0.001036638],"category_scores_gemma":[0.0006864587,0.0004812645,0.0002580261,0.00054164,0.0009986092,0.0003561604,0.0001063518,0.0005087123,0.0003921689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004343818,"about_ca_system_score_gemma":0.00345171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005472891,"about_ca_topic_score_gemma":0.0005949424,"domain_scores_codex":[0.9961393,0.0004719385,0.001367217,0.0005956496,0.0007462634,0.0006795625],"domain_scores_gemma":[0.9974906,0.0006213827,0.0005780436,0.0004232242,0.0002068791,0.0006798489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3001349,0.1175363,0.1585328,0.003161604,0.01456632,0.02343001,0.100574,0.002501862,0.009756983,0.07314406,0.06005787,0.1366033],"study_design_scores_gemma":[0.8785456,0.01848358,0.04605879,0.001976826,0.002543255,0.0006397219,0.0006138114,0.004631635,0.01430767,0.01157525,0.01950103,0.001122851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819058,0.002838972,0.00003328679,0.009475622,0.002752718,0.00169574,0.0003745203,0.00003898699,0.0008843117],"genre_scores_gemma":[0.9728541,0.0002137809,0.01331571,0.001063033,0.001000658,0.0001184626,0.0007212272,0.00006042367,0.0106526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5784107,"threshold_uncertainty_score":0.9998766,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166042057","doi":"10.1007/s10637-011-9660-2","title":"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Refractory (planetary science); Pharmacology; Internal medicine; Adverse effect; Gastroenterology","authors":[{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Swaminathan P. Iyer","is_ca":false},{"name":"Wendy Stock","is_ca":false},{"name":"Martin S. Tallman","is_ca":false},{"name":"Gregory A. Curt","is_ca":false},{"name":"J. Li","is_ca":false},{"name":"Anna Osmukhina","is_ca":false},{"name":"Kang Wu","is_ca":false},{"name":"Dennis Huszar","is_ca":false},{"name":"G. Borthukar","is_ca":false},{"name":"Stefan Faderl","is_ca":false},{"name":"Guillermo Garcia‐Manero","is_ca":false},{"name":"Tapan M. Kadia","is_ca":false},{"name":"Kamalesh K. Sankhala","is_ca":false},{"name":"Olatoyosi Odenike","is_ca":false},{"name":"Jessica K. Altman","is_ca":false},{"name":"Mark D. Minden","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03847222243353014,"gpt":0.3291154967498259,"spread":0.2906432743162958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005970275,0.0002748343,0.0004007142,0.0002372766,0.0001167926,0.00001764036,0.0003194234,0.00006191314,0.0001397759],"category_scores_gemma":[0.0001637223,0.0001931667,0.00004457119,0.00052485,0.0003721228,0.0002231638,0.0003528452,0.0005731001,0.00001002486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006057854,"about_ca_system_score_gemma":0.001065714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004689932,"about_ca_topic_score_gemma":0.00004879152,"domain_scores_codex":[0.9974259,0.0001939103,0.0006297021,0.0004659768,0.0009329712,0.0003515939],"domain_scores_gemma":[0.9982737,0.0002371287,0.0001781974,0.0004084599,0.0004217133,0.0004808569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01044609,0.008271093,0.9262602,0.0001309479,0.0007063599,0.0000591102,0.02982171,0.0001804128,0.009009643,0.0001833867,0.002401004,0.01253003],"study_design_scores_gemma":[0.04288195,0.005197128,0.9385398,0.0001639393,0.0004085249,0.000007994744,0.0009889134,0.004094358,0.005920364,0.0002228865,0.001202998,0.0003711582],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956576,0.000020929,0.00008702264,0.001283975,0.00008778238,0.002173681,0.00008308518,0.00002848228,0.0005774322],"genre_scores_gemma":[0.9940418,0.00002091148,0.003813645,0.001519801,0.00009111222,0.00004577874,0.00009023008,0.00004327668,0.0003334149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03243586,"threshold_uncertainty_score":0.7877109,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2020555572","doi":"10.1007/s10637-013-0055-4","title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Lapatinib; Pharmacokinetics; Cmax; Medicine; Meal; Tolerability; Pharmacology; Internal medicine; Gastroenterology; Adverse effect; Cancer; Breast cancer; Trastuzumab","authors":[{"name":"Lot A. Devriese","is_ca":false},{"name":"Kevin M. Koch","is_ca":false},{"name":"Marja Mergui‐Roelvink","is_ca":false},{"name":"Gemma M. Matthys","is_ca":false},{"name":"Wen Wee","is_ca":false},{"name":"André Robidoux","is_ca":true},{"name":"Joe Stephenson","is_ca":false},{"name":"Quincy S. Chu","is_ca":false},{"name":"Keith Orford","is_ca":false},{"name":"Leanne Cartee","is_ca":false},{"name":"Jeff Botbyl","is_ca":false},{"name":"Nikita Arya","is_ca":false},{"name":"Jan H.M. Schellens","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005263758791417631,"gpt":0.2631291230371833,"spread":0.2578653642457657,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002516398,0.000134338,0.0002574273,0.0001137713,0.00001987565,0.000005748877,0.00003955751,0.00002785,0.00003773122],"category_scores_gemma":[0.0000555253,0.0001020385,0.00002121388,0.0001596684,0.0001267428,0.0001129097,0.00001401238,0.00007558187,0.000008064832],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005539643,"about_ca_system_score_gemma":0.0001361138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002648702,"about_ca_topic_score_gemma":0.000007886572,"domain_scores_codex":[0.9990535,0.00002744965,0.0002730681,0.0001743527,0.0003386723,0.0001330008],"domain_scores_gemma":[0.9991973,0.0001715408,0.0001793046,0.00009740559,0.0001911992,0.0001632695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001966741,0.003137805,0.8396409,0.002622372,0.0008887839,0.00002283243,0.0133456,0.009634717,0.07333986,0.003969964,0.007156626,0.04427384],"study_design_scores_gemma":[0.01350886,0.000914335,0.8480159,0.0009201085,0.0001324183,5.654957e-7,0.00004953848,0.0001358164,0.1337522,0.002410703,0.00003284818,0.0001267362],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979241,0.00006894345,0.00001153958,0.0006507307,0.00006108776,0.0009324133,0.00003486499,0.00001156507,0.0003047593],"genre_scores_gemma":[0.9968016,0.00001487946,0.002156691,0.0004890544,0.00003131623,0.00005656583,0.0001054232,0.00001821094,0.0003263128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06041232,"threshold_uncertainty_score":0.4161009,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068833931","doi":"10.1007/s10637-008-9184-6","title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Calcitriol; Medicine; Pancreatic cancer; Internal medicine; Oncology; Cancer; Cancer research; Calcium","authors":[{"name":"Charles D. Blanke","is_ca":true},{"name":"Tomasz M. Beer","is_ca":false},{"name":"Kendra Todd","is_ca":false},{"name":"Motomi Mori","is_ca":false},{"name":"Michelle K. Stone","is_ca":false},{"name":"Charles D. Lopez","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04046030513904524,"gpt":0.3491620148261989,"spread":0.3087017096871537,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002130944,0.0002800381,0.0009837517,0.0002818842,0.0001431421,0.000005434133,0.0001534485,0.00007173894,0.0003860289],"category_scores_gemma":[0.0005125595,0.0001913462,0.00004978412,0.0009298581,0.0003879614,0.0001725789,0.00005114723,0.0002721975,0.00001298041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002438814,"about_ca_system_score_gemma":0.003255414,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001719557,"about_ca_topic_score_gemma":0.000523707,"domain_scores_codex":[0.9972801,0.0001700424,0.0007553686,0.0004355416,0.0009404283,0.000418563],"domain_scores_gemma":[0.9981403,0.000345585,0.0002820714,0.0003254868,0.0004887829,0.0004177544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01481394,0.01368773,0.9450971,0.0002721636,0.0009662712,0.0002008155,0.01424676,0.0007068865,0.0009756032,0.0000679025,0.000703305,0.00826146],"study_design_scores_gemma":[0.1504235,0.0347892,0.8069507,0.001360992,0.001032471,0.00003684543,0.001175645,0.001405788,0.001833617,0.0003590452,0.000132733,0.0004994188],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961692,0.0001736769,0.0001086994,0.0003229294,0.00002873668,0.002650119,0.00002875102,0.00003719485,0.0004806888],"genre_scores_gemma":[0.9918618,0.00007859047,0.004056092,0.0003266915,0.00003991132,0.0003054143,0.000110413,0.00003280563,0.00318826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1381464,"threshold_uncertainty_score":0.7802872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","authors":[{"name":"Glenwood Goss","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Wilson H. Miller","is_ca":true},{"name":"Ian Lorimer","is_ca":true},{"name":"David J. Stewart","is_ca":true},{"name":"Gerald Batist","is_ca":true},{"name":"D A E Parolin","is_ca":true},{"name":"Peter Hanna","is_ca":true},{"name":"S. Stafford","is_ca":true},{"name":"Jennifer Friedmann","is_ca":true},{"name":"William R. Walsh","is_ca":false},{"name":"Sara Mathews","is_ca":false},{"name":"L. Douglas","is_ca":true},{"name":"Lesley Seymour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1409265698095374,"gpt":0.4577079910447914,"spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003024252,0.0002771067,0.001072753,0.0002270653,0.00008844762,0.00001377334,0.000660679,0.00009034017,0.00009407355],"category_scores_gemma":[0.003762177,0.0001754364,0.0001438303,0.001418557,0.000923373,0.0002301941,0.0002114604,0.0006048689,6.402267e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000524621,"about_ca_system_score_gemma":0.02490734,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2103229,"about_ca_topic_score_gemma":0.3048217,"domain_scores_codex":[0.9914793,0.001045,0.002572709,0.0004592684,0.004133163,0.0003105111],"domain_scores_gemma":[0.9956384,0.0006858687,0.00159283,0.0004584101,0.001241681,0.0003828263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001273283,0.01691784,0.947262,0.0001357455,0.0005404166,0.00000200083,0.007089611,0.003322297,0.0001217685,0.0003112383,0.01689153,0.006132259],"study_design_scores_gemma":[0.04801336,0.002802613,0.9426417,0.0009089281,0.0001960143,0.000001744044,0.001168288,0.0006381269,0.001038063,0.0008663049,0.001525231,0.0001996695],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893396,0.00004411583,0.000001650054,0.004982414,0.0002327543,0.005060238,0.0002031437,0.00000991382,0.0001261104],"genre_scores_gemma":[0.9973891,0.000001920867,0.001137484,0.0005896441,0.0003268343,0.0002017729,0.00005339641,0.00002932783,0.0002705449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0944988,"threshold_uncertainty_score":0.9806206,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}